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1. Abstract 
Efficient immunosurveillance is a major factor in protecting the individual against cancer. 
Components of the innate immune system like neutrophilic granulocytes and type I IFNs 
were demonstrated to significantly influence this complex process by altering tumor 
angiogenesis and growth. Consistently, many neutrophil activities seem to be controlled by 
endogenous IFN-. Nevertheless, little is known about its detailed impact on life span and 
polarization of such cells. Moreover, whether and how type I IFN is induced in the tumor 
context and from which cellular sources it is derived is not clear. These issues were addressed 
in the present study. 
Using different transplantable tumors in an IFN- reporter mouse model, it could be 
demonstrated for the first time that IFN- is induced in solid tumors. This induction is 
mediated in a STING-IRF3/5 dependent manner and tumor infiltrating myeloid dendritic cell 
were identified as a main cellular source of this cytokine. 
Furthermore, the present results provide evidence that endogenous IFN- is regulating 
apoptosis, maturation and turnover of pro-angiogenic tumor infiltrating neutrophils by 
influencing both, the extrinsic as well as the intrinsic apoptosis pathways. Accordingly, the 
life span of tumor associated neutrophils (TANs) was remarkably prolonged in tumor bearing 
Ifnb1

 mice, compared to wild type (WT) controls. Lower expression of Fas, reactive 
oxygen species, active caspase 3 and 9 as well as a change in expression ratio of pro- and 
anti-apoptotic members of the Bcl-2 family were observed under such conditions. In addition, 
the major apoptosome constituent Apaf-1 was downregulated. In line with inhibition of 
apoptosis and increased neutrophil longevity in the absence of endogenous IFN-β, a strong 
enhancement of G-CSF expression and PI3 kinase phosphorylation was detected.  
During the present study substantial evidence was accumulated supporting the role of 
endogenous IFN- as factor responsible for the induction of an N1 anti-tumor neutrophil 
polarization. Hence, a significant down regulation of N1 associated neutrophil features such 
as ICAM1 expression, TNF- production and tumor killing capacity were observed in 
Ifnb1

 mice, compared to WT controls. Of note, exogenous IFN- therapy of tumor bearing 
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WT animals significantly influenced neutrophil polarization at the primary tumor site and in 
the pre metastatic lung, inducing a N1 anti-tumor neutrophil phenotype.  
Taken together, the present work provides important insight into the molecular mechanisms 
underlying type I IFN-mediated cancer immunosurveillance via the polarization of tumor 
associated neutrophilic granulocytes. 
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2. Introduction 
Despite substantial research effort, cancer is still the second most common cause of death in 
the industrialized world with rising incidence. Therefore, understanding the molecular 
mechanisms of this disease is of utmost importance for the development of new therapies. 
Especially in the light of several recent findings, the innate immunosurveillance against 
cancer needs to be carefully investigated. 
2.1. The type I IFN system 
Type I interferons (IFNs) were first described more than 50 years ago as factors responsible 
for the phenomenon of viral interference (Isaacs and Lindenmann, 1987). This monomeric 
family of cytokines includes at least 12 subtypes of IFN-, IFN-, IFN, IFN- and IFN-
(Pestka et al., 2004) in mice and humans. All these type I IFNs signal via a common cell 
surface receptor IFNAR that is virtually present on every cell type (Pestka et al., 2004). 
Therefore, they are involved in the regulation of numerous biological processes central to 
innate and adaptive immunity. 
2.1.1. Induction of type I IFNs 
The expression of type I IFNs, such as IFN-, is rapidly induced after recognition of different 
pathogen associated molecular patterns (PAMPS) or danger associated molecular patterns 
(DAMPs) by host pathogen recognition receptors (PRRs) including the Toll-like receptors 
(TLRs), RIG-like receptors (RLRs) or cytosolic DNA receptors (CDRs) (Keating et al., 
2011). Besides viral and bacterial RNA or DNA, viral glycoproteins or bacterial cell surface 
compounds like lipopolysaccharide (LPS), also host DNA is capable to induce significant 
type I IFN responses (Fuertes et al., 2013). The signaling pathways that lead to IFN induction 
differ, depending on the stimulus and the responding cell type. Nevertheless, they involve 
common signaling molecules such as IFN regulatory factors (IRFs) or nuclear-factor-, that 
bind to the IFNA as well as the IFNB promoters to initiate gene expression as depicted in 
figure 2.1. (González-Navajas et al., 2012). 
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Figure 2.1. Major pathways of IFN induction. CDRs, RLRs and TLRs are the main PRRs that 
induce type I IFN responses. They signal via STING, IPS-1/MAVS, TRIF or MyD88, the kinase 
TBK1 and IRFs and in the end lead to the expression of type I IFN genes upon the recognition of 
potentially dangerous substances like dsDNA, CpGDNA, ss/ds RNA or LPS. (Fuertes et al., 2013) 
TLRs are the key sensors for microbial invasion in mammals and activate innate defense 
mechanisms crucial for host survival (Medzhitov, 2001). In mice and humans six TLRs are 
known to induce type I IFNs (Noppert et al., 2007). TLR2, TLR3, TLR4, TLR7, TLR8 and 
TLR9 sense various bacterial and viral products and signal via TIR-domain-containing 
adaptor protein inducing IFN (TRIF) or myeloid differentiation-associated primary-response 
protein 88 (MyD88) to induce a type I IFN response (Monroe et al., 2010; Dietrich et al., 
2010).  
However, mice can also produce type I IFNs in response to RNA and DNA ligands 
independently of TLR signaling. These TLR-independent pathways include PRRs like 
retinoic-acid-inducible gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA5) 
and DNA-dependent activator of IRFs (DAI) (González-Navajas et al., 2012). RLRs like 
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RIG-I, on the one hand, signal via the adaptor protein MAVS (mitochondrial antiviral 
signaling protein, Cardif, IPS-1) and CDRs like DAI activate the endoplasmic reticulum-
resident protein STING (stimulator of IFN genes). Recently cGAS has been described as 
additional sensor for intracellular DNA. Upon binding of DNA this enzyme generates a 
second messenger (cyclic GMP-AMP) which also activates STING (Cai et al., 2014). Both 
adaptor proteins are known to activate the TANK-binding kinase 1 (TBK1) which 
subsequently phosphorylates IRF3 and IRF7 (Keating et al., 2011). Upon activation, IRF3 
forms homodimers or heterodimers with IRF7, translocates to the nucleus and activates the 
transcription of type I IFN genes. As a rule, IFN- is produced first initiating a cascade of 
IFN- via autocrine and paracrine loops (Lienenklaus et al., 2008). Here, constitutively 
expressed IRF-3 is primarily involved in the induction of IFN-β in the early phase of the 
response, whereas IRF-7, the expression of which is induced by IFN-β, functions in the later 
phase to induce IFN-αs as well as additional IFN-β (Taniguchi and Takaoka, 2002). Only 
plasmacytoid dendritic cells (pDCs) remain an exception and can produce large amounts of 
IFN- without prior presence of IFN- (Barchet et al., 2002). In addition to IRF-3 and 7, 
other IRFs are involved in type I IFN induction and regulation, e.g. IRF-5 is crucial in 
MAVS-dependent IFN activation in myeloid dendritic cells (mDCs) (Lazear et al., 2013). 
Interestingly, the activation of IRF5 seems to be very cell type specific and recently multiple 
IRF5 splice variants with differential cellular localization and regulation have been identified, 
further adding to the complexity of type I IFN induction and signaling (Mancl et al., 2005). 
Besides IRF3, IRF5 and IRF7 that positively regulate type I IFN induction also negative 
regulators are known, namely, IRF2, IRF4 and IRF 8 (Noppert et al., 2007; Pelka and Latz, 
2013). 
2.1.2. Signaling pathways of type I IFNs 
All type I IFNs signal via a common IFN-/ receptor (IFNAR), that is ubiquitously 
expressed on most cells in mice and men. It consists of two different subunits, IFNAR1 and 
IFNAR2 (Honda and Taniguchi, 2006), and is constitutively associated with Janus kinase 1 
(JAK1) and non-receptor tyrosin kinase 2 (TYK2) (Platanias, 2005a). IFNAR engagement 
results in the activation of these kinases that subsequently phosphorylate and activate 
different signal transducer and activator of transcription (STAT) family members. In the vast 
Introduction 
6 
 
majority of cells this includes STAT1, STAT2, STAT3 and STAT5. STAT4 and STAT6 
however, can likewise be activated by type I IFN signaling in lymphocytes (Gonzalez-
Navajas et al., 2012). 
Upon activation, STAT1 and STAT2 recruit IRF9 and form a complex called IFN-stimulated 
gene factor 3 (ISGF3). This complex migrates to the nucleus and induces the expression of 
IFN-stimulated genes (ISGs) via binding to IFN-stimulated response elements (ISREs) in the 
promoter regions of the different ISGs (Platanias, 2005b). Besides this classical pathway, 
STAT1 or STAT3 homodimers can be formed and bind to IFN--activated site (GAS) 
enhancer elements or STAT3-binding elements (SBEs) to promote ISG expression. In 
addition to STAT1, 2 and 3, other STAT family members were reported to mediate type I 
IFN signaling in a cell type specific manner. In general, the variance in STAT expression and 
its dependence on cell type, activation and differentiation state play a major role in the 
regulation of the diverse outcomes of IFNAR signaling (Hervas-Stubbs et al., 2011). 
Moreover, there is evidence for STAT-independent type I IFN signaling pathways, 
transduced via mitogen activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K), 
NF-B, Ras-related protein 1 (Rap 1) or Insulin receptor substrate 1 and 2 (IRS 1/2). An 
overview of these various IFNAR signaling pathways is depicted in figure 2.2. Interestingly, 
MAPK, PI3K and NF-B pathways involve immunoreceptor tyrosine-based activation 
motives (ITAMs) used by immunoreceptors such as the T cell or B cell receptor and some FC 
receptors. This indicates a cross-talk among IFNAR and multiple receptors in immune cells 
(Hervas-Stubbs et al., 2011).  
Finally, several negative regulators of IFNAR signaling help to fine tune the whole system, 
including suppressors of cytokine signaling (SOCS) 1 and 3 (Song and Shuai, 1998), the 
protease UBP43 (Ritchie et al., 2004) or different members of the PIAS (protein inhibitor of 
activated STAT) family (Liu et al., 2004).  
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Figure 2.2. Type I IFN signaling pathways. Upon IFNAR engagement different signaling 
pathways including JAK-STAT, CRK, PI3K, NF-B or MAPK pathway can be induced depending 
on the target cell and introduce a specific IFN gene expression profile. (Hervas-Stubbs et al., 
2011) 
2.1.3. General functions of type I IFNs 
As a result of the ubiquitous expression of IFNAR and the numerous signaling pathways 
introduced upon receptor engagement, type I IFNs influence a broad variety of cellular 
processes. Micro array studies have identified a set of at least 1000 ISGs that were induced or 
repressed by type I IFNs. Besides inflammatory, anti-microbial and anti-viral ISGs also 
immunoregulatory ISGs, pro- and anti-apoptotic ISGs, as well as ISGs influencing 
proliferation and maturation of the target cells were identified (de Veer et al., 2001).  
The first functional ability described for type I IFNs was their anti-viral capacity. 
Mechanistically the type I IFN mediated inhibition of viral replication depends on cell type 
and virus. In general, multiple steps of the viral life cycle, such as viral entry, transcription, 
initiation of translation, maturation, assembly and release are targeted by ISGs (Noppert et al. 
2007). For example 2´-5´oligodeadenylate synthetase is an IFN dependent enzyme that can 
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induce the degradation of viral RNA (Zhou et al., 1993). Another type I IFN induced enzyme 
is protein kinase R (PKR). By the phosphorylation of different substrates PKR can block the 
translation of viral RNA (Lu et al., 1999). Furthermore, Mx proteins as typical anti-viral ISG 
products oligomerize around the viral nucleocapsid structure. Conformational changes upon 
GTP binding and/or hydrolysis then lead to disintegration of the infecting nucleocapsids (Gao 
et al., 2011; Haller et al., 2010). 
Besides the anti-viral action type I IFNs like IFN- strongly influence proliferation and 
maturation of certain cell subsets. On the one hand they repress myelopoiesis (Hwang et al., 
1995) or proliferation of effector T cells (Petricoin et al., 1997) but on the other hand they 
may stimulate the survival of memory T cells (Sun et al., 2000). Moreover, type I IFNs are 
involved in cell cycle control by influencing c-myc expression (Hu et al., 2005), modulating 
cycline-dependent kinase (cdks) activity (Kumar and Atlas, 1992) and regulating the 
production of growth factors as well as their receptors (Noppert et al. 2007). In addition to 
this anti-proliferative action, type I IFNs influence the expression of several constituents of 
the intrinsic and extrinsic apoptosis pathways like BCL2 proteins, caspases or TNF family 
receptors and ligands. Therefore, they do not only exert cytostatic but also cytotoxic effects 
mediated via FADD/caspase 8 signaling (Chawla-Sarkar et al., 2003). 
More recently, evidence accumulated indicating type I IFNs to be central regulators of innate 
and adaptive immune responses. An overview of the immunomodulatory effects assigned to 
type I IFNs is schematically depicted in figure 2.3.(Gonzalez-Navajas et al., 2012). 
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Figure 2.3. Immuno modulatory functions of type I IFNs. Type I IFNs influence several 
cellular components of the innate and adaptive immune system such as T cells, B cells, NK cells, 
DCs and macrophages (Bogdan et al., 2004) 
Regarding the innate immune system, type IFNs have been reported to regulate NK cell 
functions like their killing ability, IFN- production or survival (Nguyen et al., 2002). 
Similarly, the monocyte and macrophage compartment is strongly influenced by type I IFNs. 
They seem to stimulate the antibody dependent cytotoxicity of macrophages, the 
differentiation of monocytes into DCs with high antigen presentation capabilities and they 
repress or induce the production of different macrophage derived cytokines (Bogdan et al., 
2004).  
Not only innate immune cells are affected by the presence of type I IFNs. With regard to the 
regulation of adaptive immune responses, type I IFNs have been shown to have effects on 
DCs, B cells and T cells. In addition to driving Th1 immune responses (Proietti et al., 2002), 
they can influence T cell proliferation and survival (Tough, 2012) and support CTL 
differentiation via the induction of T-bet expression (Wiesel et al., 2012). Besides cellular 
immunity, type I IFNs were demonstrated to play a crucial role for the development of 
humoral immune responses by supporting B cell survival and class switch (Kiefer et al., 
Introduction 
10 
 
2012). In face of these potent effects of type I IFNs on the host immune system, a strong 
impact on cancer progression and development is a logical consequence. 
2.1.4. The role of type I IFNs in tumor development 
Shortly after the discovery of IFN by Isaacs and Lindenmann in 1957, the investigation of its 
role in tumor biology started. Nowadays, a strong anti-tumor effect of type I IFNs is well 
established and can be attributed to both, direct and indirect actions on tumor cells. It is 
known that type I IFN can directly induce growth arrest and apoptosis in certain tumor cells 
via the induction of pro-apoptotic genes like TRAIL and Fas or exert its cytostatic capacity 
via IRF9 (Bekisz et al., 2013). Additionally, IFN- can upregulate the expression of the 
tumor suppressor p53 and inhibit transformation of mouse embryonic fibroblasts in vitro 
(Takaoka et al., 2003). Thus, the immunoregulatory potential of type I IFNs is of utmost 
importance for cancer biology. For instance, type I IFNs can enhance the expression of 
histocompatibility antigens, therefore allowing the recognition of tumor antigens that leads to 
the induction of an anti-tumor immune response (Wan et al., 2012). On the other hand, type I 
IFNs can stimulate certain subsets of immune cells that are important for cancer 
immunosurveillance or facilitate their recruitment (Hervas-Stubbs et al., 2011). Finally, type 
I IFNs play an important role in the process of cancer immunoediting, proving their 
significance during tumor development (Dunn et al., 2006).  
Interestingly, many tumors show alterations in IFN response pathways. For example 
glioblastoma cells upregulate USP18, a negative regulator of IFN responses (Sgorbissa et al., 
2011). Similarly, in melanoma patients genetic variants of type I IFN genes were 
demonstrated to exert a significant impact on survival and therapeutic response (Lenci et al., 
2012), again highlighting the therapeutic potential of type I IFNs or their targets for cancer 
therapy. 
2.1.5. Type I IFNs in cancer therapy 
Intron-A (IFN-2b, Schering-Plough) and Roferon-A (IFN-2a, Hoffmann-La Roche) were 
the first FDA-licensed IFNs for tumor therapy. Initially, IFNs were used to treat hairy cell 
leukemia, but since then they were tested as therapeutic agents in a broad variety of cancers 
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(Fig. 2.4.) such as chronic myeloid leukemia, melanoma, lymphoma, HIV-associated Kaposi 
sarcoma or renal cell carcinoma (Wang et al., 2011). 
 
Figure 2.4. Human cancer targets of interferon therapy. IFNs are in clinical use for the 
treatment of a wide variety of solid and hematologic malignancies (Wang et al., 2011). 
In patients suffering from high-risk cutaneous melanoma high-dose adjuvant IFN- therapy 
improved both, relapse-free as well as overall survival (Mocellin et al., 2013). Also in the 
treatment of hematologic neoplasias such as chronic myeloid leukemia, polycythemia vera or 
hairy cell leukemia, IFN- was demonstrated to induce remission and serve as a suitable 
maintenance therapy (Anguille et al., 2011). Interestingly, in CML patients IFN- seems to 
activate cytotoxic T cells resulting in a long-term immunological control of neoplastic cells 
(Burchert et al., 2003).  
Another tumor entity successfully treated with IFN-, especially in combination with 
monoclonal antibodies against tumor antigens, are metastatic renal cell carcinoma. Of note, a 
combination of bevacizumab or sunitinib with IFN- is the current standard of care for 
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advanced renal cell carcinoma in Germany (Melichar et al., 2008). Moreover, IFN- in 
combination with temozolomid results in a favorable outcome for patients suffering from 
primary glioblastoma multiforme (Motomura et al., 2011). Taken together, type I IFNs alone 
or in combination with other drugs seem to exhibit an immunostimulatory effect and help to 
improve the therapeutic outcome of a wide range of solid and hematologic tumors (Wang et 
al., 2011). Therefore, understanding the molecular mechanisms targeted by IFN therapy 
could help to further improve their therapeutic use and potential. 
2.2. Neutrophilic granulocytes 
Neutrophilic granulocytes were first identified in the late 19
th
 century by Paul Ehrlich who 
described them as polymorph nuclear cells with a tendency to retain neutral dyes. 
Evolutionary, neutrophils with functional similarity to mammalian neutrophils were present 
already in amphibians and bony fish. They play a major role in early immune responses and 
are central for host defense against bacterial pathogens (Amulic et al., 2012a). In contrast to 
humans, they are less abundant in other species. 
2.2.1. Neutrophil development, life span and general functions 
In the adult bone marrow, neutrophils differentiate from multipotent hematopoietic precursor 
cells called myeloblasts. During the maturation process, they pass different intermediate 
stages (Fig. 2.5) that can be characterized by the presence of different granules (Borregaard, 
2010). These granules can be divided into three subsets (primary/azurophilic, 
secondary/specific and tertiary/gelatinase) each containing a specific composition of proteins, 
mainly enzymes, that are produced according to the genetic program active in the different 
neutrophil maturation stages (Liu et al., 2013). Azurophilic granules are largest in size and 
produced first during neutrophil maturation. Besides other anti-microbial proteins they 
contain myeloperoxidase (MPO), the main player in oxidative burst (Faurschou and 
Borregaard, 2003). The specific or secondary granules are smaller and can be characterized 
by the presence of lactoferrin and lysozyme. As the latter ones tertiary granules are MPO 
negative. They are mainly produced in metamyelocytes and band cells and comprise different 
metalloproteinases such as gelatinase (Faurschou and Borregaard, 2003). Besides the 
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different cargo, the release kinetics of these three granule subsets vary from difficult 
(azurophilic granules) to fast and easy (tertiary granules) (Borregaard and Cowland, 1997). 
 
Figure 2.5. Neutrophil maturation and granule formation. The process of neutrophil 
maturation is accompanied by the formation of different granule subclasses each containing a 
specific composition of proteins (Amulic et al., 2012b). 
In mice as well as in humans, neutrophil mobilization from bone marrow is tightly regulated 
by the expression of CXCR2 and CXCR4 chemokine receptors and their ligands. Meanwhile 
CXCL12 secreted by bone marrow stromal cells binds to CXCR4 and provides a key 
retention signal to neutrophils, the G-CSF induced CXC chemokines CXCL1 and CXCL2 
signal via CXCR2 to initiate neutrophil mobilization (Eash et al., 2010). In general, the 
cycling time of neutrophils is comparably short. They tend to leave circulation after 6 to 8 
hours upon the recognition of inflammatory sites intended by the presence of host- or 
pathogen-derived chemo attractants (Amulic et al., 2012a). Therefore, they bind to P-
selectins, E-selectins and ICAMs on activated endothelial cells, extravasate into the target 
tissue and become activated during transmigration (Fig.2.6.). 
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Figure 2.6. Migration and tissue infiltration of neutrophils. Trans-endothelial migration of 
neutrophilic granulocytes is a step-wise process facilitated by adhesion molecules present on 
activated endothelial cells and neutrophils (Mayadas et al., 2014) 
Following gradients of chemoattractants such as fMLP, CXCL1, CXCL2 or IL-8 (only in 
humans) formation of the oxidative burst machinery is conducted. Besides the initiation of 
antimicrobial reactions, like receptor-mediated phagocytosis of pathogens, degranulation and 
the formation of neutrophil extracellular traps (NETs), neutrophil activation is accompanied 
by the secretion of pro-inflammatory cytokines crucial for the establishment of fully 
functional immune responses (Borregaard, 2010).  
Therefore, patients suffering from genetic disorders or diseases associated with neutropenia 
display a frightening short survival. If treatment is lacking such patients die due to severe, 
non-resolving bacterial infections. 
2.2.2. Neutrophils in immune regulation 
Since neutrophils were long regarded as simple, terminally differentiated and short-lived 
effector cells, their immunoregulatory capacity has been largely underestimated. Nowadays, 
emerging evidence suggests that neutrophils have a strong impact on both innate and 
adaptive immunity, and cooperate with other immune cells in a complex cross talk as 
depicted in figure 2.7. (Mantovani et al., 2011).  
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Figure 2.7. Neutrophil-immune cell cross talk in inflammation. During inflammation 
neutrophils undergo a bilateral crosstalk with macrophages, DCs, T cell, B cells and NK cells 
essential for a functional immune response (Mantovani et al., 2011). 
Several neutrophil derived products such as lactoferrin, -defensins or CCL3 were reported 
to have a chemotactic effect on other myeloid cells, such as DCs (Yang et al., 2009). In 
addition, direct contact with neutrophils can facilitate maturation of DCs and increase their 
antigen presentation efficacy (Alfaro et al., 2011). Neutrophil-DC interactions are not 
restricted to processes of host defense. For example in autoimmune diseases like SLE the 
release of NETs can be linked to disease exacerbation and the activation of DCs. 
Interestingly, the IFN- secreted due to this interaction further enhances NET formation 
(Lande et al., 2011).  
Another bilateral regulation is described for neutrophils and T cells. Neutrophils can act as 
APCs and express MHC class II to induce Th1 or Th17 polarization of CD4
+
 T cells (Abi 
Abdallah et al., 2011). Interestingly, neutrophil antigen presentation is not restricted to the 
site of inflammation, but can also occur in lymph nodes and bone marrow (Beauvillain et al., 
2007, 2011; Duffy et al., 2012). In addition to stimulatory effects neutrophils are known to 
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inhibit T cell proliferation via the secretion of arginase or reactive oxygen species (ROS) 
(Mayadas et al., 2010).  
Besides their effects on DCs and T cells, B cells are also influenced by neutrophils. Their 
survival and activation is facilitated by neutrophil derived cytokines like BAFF (B cell 
activating factor) or APRIL (a proliferation-inducing ligand) (Scapini et al., 2008). In spleen 
neutrophils can indeed be found next to the marginal zone where they carry out B cell 
support and are termed B-cell helper neutrophils (NBH) (Cerutti et al., 2013). 
Recently, several interactions of neutrophils and NK cells have been elucidated indicating 
that neutrophils regulate NK cell maturation and function (Jaeger et al., 2012). On the other 
hand, activated NK cells produce neutrophil survival factors such as GM-CSF that initiate a 
positive feedback loop and augment inflammatory responses (Costantini et al., 2011).  
Last but not least, neutrophils and macrophages interact and influence each other. Upon 
activation, neutrophils produce large amounts of monocyte/macrophage attracting 
chemokines like CCL2, CCL3, CCL19 or CCL20 that recruit these cells to the site of 
inflammation (Amulic et al., 2012b). Moreover, neutrophil granule components can increase 
the anti-microbial activity and support the phagocytic capacity of macrophages (Soehnlein et 
al., 2009). Of particular importance is the interaction of macrophages and neutrophils in the 
resolution phase of inflammation. Here, macrophages are responsible for the clearance of 
apoptotic neutrophils that in turn induces an M2 anti-inflammatory phenotype in 
macrophages and helps tissue repair (Filardy et al., 2010). Besides, neutrophils actively 
contribute to the resolution of inflammation by the production of anti-inflammatory lipid 
mediators, resolvins and protectins as well as by cytokine scavenging via different CC and 
CXC chemokine receptors (Mantovani et al., 2011).  
2.2.3. Neutrophil cell death – apoptosis, NETosis and clearance 
In contrast to cells of the adaptive immune system, neutrophils need no activation to acquire 
an effector phenotype. In accordance with their pleiotropic function, neutrophils are equipped 
with a large array of effector molecules that can potentially harm the host. Therefore, 
neutrophil cell death and clearance need to be tightly controlled (Witko-Sarsat et al., 2011). 
In general, the mode of neutrophil cell death is context dependent. Besides apoptosis, they 
can undergo necrosis, NETosis or autophagy (Kennedy and DeLeo, 2009).  
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Neutrophil apoptosis is known to play a critical role during the resolution of inflammation 
and is necessary to retain homeostasis (Geering and Simon, 2011). It can be induced by both, 
the extrinsic as well as the intrinsic apoptosis pathway (Fig. 2.8.) (Gabelloni et al., 2013). 
 
Figure 2.8. Neutrophil apoptosis pathways. Neutrophil apoptosis can be induced via the 
intrinsic and the extrinsic death receptor mediated pathway (Fox et al., 2010) 
As a trigger for the extrinsic apoptosis pathway mainly macrophage released death receptor 
ligands such as Fas ligand or TNF- are important. After binding to their receptors on the 
neutrophil cell surface they induce formation of the death-inducing signaling complex 
(DISC) that subsequently catalyzes the activation of initiator caspases 8 or 10. This finally 
leads to the induction of apoptosis conducted by effector caspase 3 (Galluzzi et al., 2012b). 
Neutrophils can be characterized as type II cells i.e. their extrinsic apoptosis pathway is 
mitochondria-dependent and they produce low amounts of active caspase 8. To this end, 
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neutrophilic death receptor signaling requires strengthening by an interplay with the intrinsic 
apoptosis pathway initiated by truncated Bid (Fox et al., 2010).  
The intrinsic apoptosis pathway is responsible for the propagation of spontaneous neutrophil 
apoptosis. Here, mitochondria associated proteins of the BCL-2 family regulate 
mitochondrial outer-membrane permeabilization upon which cytochrome c is released into 
the cytoplasm. Subsequently, it induces apoptosome formation via Apaf-1 (apoptotic protease 
activating factor 1) oligomerization, leading to the activation of caspase 9. This initiator 
caspase in turn can cleave and activate effector caspases to induce cell death (Galluzzi et al., 
2012b). Interestingly, the mitochondrial apoptosis pathway in neutrophils exhibits a 
surprisingly low threshold for cytochrome c that may be compensated by their comparably 
high expression level of Apaf-1 (Murphy et al., 2003). Concerning the occurrence of BCL-2 
family members, neutrophils express the pro-apoptotic proteins Bax, Bak, Bad, Bid and Bik 
as well as the anti-apoptotic regulators Mcl-1 and BCL-xL (van Raam et al., 2006). On the 
pro-apoptotic side, especially Bax plays a non-redundant role in neutrophil apoptosis (Gardai 
et al., 2004). Remarkably, the neutrophil pro-survival factor G-CSF has been shown to down-
regulate Bax expression (Dibbert et al., 1999). On the other hand, TNF-induced neutrophil 
cell death has been demonstrated to be accompanied by an increased ratio of pro-apoptotic 
Bax towards anti-apoptotic BCL-xL (Perskvist et al., 2002).  
Even though most of the mediators involved in neutrophil cell death are of general nature and 
involved in apoptosis of a broad variety of cell types, there are additional special features 
regarding neutrophils. For example ROS, that are produced in large amounts by activated 
neutrophils (Amulic et al., 2012a), seem to trigger neutrophil apoptosis via not yet fully 
understood mechanisms that involve an interplay with the classical pathway (Scheel-Toellner 
et al., 2004). Furthermore, NETosis, as a special form of neutrophil cell death, was described 
by Zychlinsky and colleagues (Brinkmann et al., 2004). During this process that is initiated 
by different pro-inflammatory stimuli such as LPS or TNF, the neutrophil nuclear 
membrane is degraded and a homogenous mass of cytoplasm and nucleoplasm is released 
into the extracellular space. Such formations, called NETs are used to entrap and kill bacteria 
(Kaplan and Radic, 2012).  
The major cells responsible for the clearance of apoptotic neutrophils are macrophages and 
DCs that sense signals exhibited by dying PMNs, e.g. lactoferrin, phosphatidylserine or 
Introduction 
19 
 
calreticulin (Bratton and Henson, 2011). This process, called efferocytosis plays a major role 
during the resolution of inflammation and for example induces the production of TGF- or 
IL-10 by reprogrammed macrophages (Mantovani et al., 2011).  
2.2.4. Neutrophils in tumor development and progression 
Since Hanahan and Weinberg postulated the first six central hallmarks of cancer, namely, 
sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling 
replicative immortality, inducing angiogenesis and activating invasion and metastasis 
(Hanahan and Weinberg, 2000), our understanding of the molecular mechanisms underlying 
this fatal disease has dramatically increased. The authors attributed to this by redefining a 
“next generation” of cancer hallmarks, that besides reprogramming energy metabolism and 
evading immune destruction, introduced two enabling characteristics i.e. genome instability 
and mutation as well as tumor-promoting inflammation (Hanahan and Weinberg, 2011). 
Indeed, the latter one is nowadays accepted to have a strong impact on most of the other 
hallmark capabilities highlighting the fact that a transformed cell alone is unable to establish 
a highly malignant and invasive lesion (Hanahan and Coussens, 2012). An overview of the 
interplay between tumor microenvironment and the hallmarks of cancer is depicted in figure 
2.9.  
Regarding the tumor-promoting effect of immune infiltration, mainly the innate arm of the 
invading immune cells has been claimed to be responsible. Besides macrophages, monocytes 
and immature myeloid cells (MDSCs), neutrophils play an imported role in this scenario 
(Galdiero et al., 2012). In the recent years, several clinical surveys have demonstrated the 
adverse prognostic effect of high neutrophil infiltration or blood neutrophilia in a broad 
variety of human cancers, including renal cell carcinoma, melanoma, glioblastoma or 
colorectal cancer (Donskov, 2013). 
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Figure 2.9. Influences of tumor stromal cells on the hallmarks of cancer. Tumor promoting 
inflammation is one of the most important hallmarks of cancer since invading immune cells 
influence almost all other cancer hallmarks (Hanahan and Coussens, 2012). 
Indeed, neutrophils seem to be able to influence most of the critical hallmarks of cancer and 
promote massively the self-sustainment of a permissive tumor microenvironment via further 
facilitating the recruitment of leukocytes towards tumor site. This is due to the huge amounts 
of CXC chemokines like CXCL1, CXCL2, CXCL3 or CXCL5 secreted by the tumor 
associated neutrophils (TAN) (Jaillon et al., 2013). Moreover, general functions of 
neutrophils, such as the production of ROS could help to create a milieu that is permissive for 
genomic instability and mutation (Campregher et al., 2008). Similarly, the sustainment of 
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proliferative signaling can be promoted by TANs. As such, neutrophil elastase can cleave the 
insulin receptor substrate-1 (IRS-1), which in turn enhances PDGFR signaling and facilitates 
the proliferation of transformed cells (Houghton et al., 2010). The third hallmark of cancer 
influenced by neutrophils is the activation of tumor cell invasion and metastasis. To this end, 
TANs secret several factors that help tumor progression, such as oncostatin M (Queen et al., 
2005) and hepatocyte growth factor (HGF) (Grenier et al., 2002).  
In addition, TANs can promote angiogenesis, another hallmark of cancer, by expressing pro-
angiogenic factors and matrix remodeling enzymes. Besides VEGF (Scapini et al., 2004), 
which is the major pro-angiogenic factor in vivo, they can secret Bv8 to induce the 
proliferation of endothelial cells (Shojaei et al., 2008). Moreover, TANs are the major source 
of MMP9, a pro-angiogenic matrix metalloproteinase (Kuang et al., 2011). Interestingly, 
matrix metalloproteinases can cleave cell-cell or cell-matrix adhesion molecules and thus 
block growth suppressing adhesion complexes (Hanahan and Coussens, 2012) or prevent 
tumor cell apoptosis (Acuff et al., 2006). Last but not least, neutrophils have strong 
immunomodulatory abilities. As already explained in chapter 2.2, they can modulate 
proliferation, maturation, recruitment, function and survival of a broad variety of immune 
cells including DCs, macrophages, monocytes, NK cell, B cells, effector T cells and 
regulatory T cells (Mantovani et al., 2011; Mishalian et al., 2014).. Under tumor conditions 
they can therefore help the tumor cells to avoid immune destruction for example by inhibiting 
T cell effector functions (Rodriguez et al., 2004) via the secretion of arginase (Rotondo et al., 
2009) 
2.2.5. Neutrophil polarization and plasticity– N1 anti-tumor vs. N2 pro-tumor 
phenotype 
The micromilieu present in tumors provides a special niche and massively influences 
invading immune cells. This concept of immune cell polarization is well established for 
macrophages (M1/M2) under inflammatory conditions (Sica and Mantovani, 2012). M1 
macrophages display a pro-inflammatory and anti-tumor phenotype and can be induced by 
IFN- alone or in combination with LPS, TNF- or GM-CSF via STAT1 signaling (Schwartz 
and Svistelnik, 2012). These classically activated macrophages produce large amounts of IL-
12, IL-23 and TNF- and thus help to initiate Th1 and Th17 responses (Krausgruber et al., 
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2011). Along this line in a tumor setting, M1 macrophages are capable to contribute to cancer 
immunosurveillance by orchestrating the T-cell-mediated tumor elimination (Schreiber et al., 
2011). M2 macrophages on the other hand display an anti-inflammatory and pro-tumor 
phenotype. Alternative activation of macrophages as such is initiated by IL-4 and IL-13 via 
STAT6 signaling (Sica and Mantovani, 2012). In addition, IL-10 can promote an M2 pattern 
of gene expression in a STAT-3-dependent manner (Lang et al., 2002). Upon M2 polarization 
macrophages start to produce high amounts of IL-10 and arginase. Therefore, they are able to 
efficiently suppress Th1 responses and attenuate inflammation. Moreover, M2 macrophages 
are known to facilitate angiogenesis and tissue remodeling (Biswas and Mantovani, 2010). 
During tumor progression the M1/M2 ratio has been reported to shift towards an M2-biased 
direction (Zaynagetdinov et al., 2011). 
In 2009 Fridlender and colleagues first described a phenotypic switch from pro- to anti-tumor 
functions for TANs. After TGF- blockade, they observed a higher frequency of 
hypersegmented, cytotoxic and pro-inflammatory neutrophils in tumors of treated vs. 
untreated animals. These neutrophils were able to activate tumor-toxic CD8
+
 T cells and 
seemed to be the target of TGF-. Neutrophil depletion blunted the therapeutic effect of 
blocking agents (Fridlender et al., 2009). Since then, the investigation of TAN polarization 
gained increasing attention. It has been demonstrated that N2 TANs accumulate during tumor 
progression (Mishalian et al., 2013) and contribute to tumor growth (Pekarek et al., 1995; 
Tazawa et al., 2003) by a plethora of mechanisms described in the previous section and 
depicted in Figure 2.10 (2.2.4). 
N1 neutrophils in contrast are tumor-toxic and inhibit tumor growth (Di Carlo et al., 2001; 
Hicks et al., 2006). Accordingly, depletion of neutrophils in cancer immunotherapies that are 
supposed to induce an N1 response abrogates therapeutic effects (Kousis et al., 2007; 
Suttmann et al., 2006). Along this line, N1 entrained neutrophils can inhibit tumor seeding in 
the pre-metastatic lung via the generation of H2O2 (Granot et al., 2011) or increase immune 
recognition of tumor cells via a neutrophil elastase dependent promotion of self-antigen 
presentation (Mittendorf et al., 2012). Moreover, direct killing of tumor cells by N1 
neutrophils via the secretion of ROS (Zivkovic et al., 2007) or antibody-dependent cellular 
cytotoxicity (Hubert et al., 2011) has been demonstrated. Besides, N1 TAN can support an 
adaptive anti-tumor immune response. Therefore, they activate DCs via direct contact or the 
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secretion of TNF- (van Gisbergen et al., 2005b; a) and modulate T cell responses under 
tumor conditions. For instance N1 neutrophils were demonstrated to recruit and activate T 
cells at tumor site by secreting chemokines like CXCL9 or CXCL10 or producing pro-
inflammatory mediators like IL-12, TNF- or GM-CSF (Fridlender et al., 2009; Scapini et 
al., 2000). Interestingly, antigen-pulsed neutrophils have also been shown to cross-present 
antigens in vitro to activate CTLs (Beauvillain et al., 2007). In addition, they help to activate 
CD4
+
 T cells and establish an anti-tumoral T cell memory (Cavallo et al., 1992). 
 
Figure 2.10. N1 vs. N2 polarization and functional properties of TAN. TGF- and IFN- are 
two potential factors influencing the functional polarization of TANs (Fridlender and Albelda, 
2012). 
Obviously, strict classification of TAN into N1 and N2 phenotypes is an oversimplification. 
More likely, these two immune phenotypes mark the extreme edges of a continuum of 
functional states that neutrophils can exhibit under tumor conditions (Mantovani et al., 2011). 
Still, it would be extremely promising to unravel the mechanism underlying polarization and 
alter the characteristics of tumor infiltrating neutrophils towards an N1 anti-tumor 
predominance. Currently, little is known about factors regulating the N1/N2 switch. On the 
one hand, TGF- is suggested to be an N2 inducer (Fridlender and Albelda, 2012). 
Meanwhile data generated by Jablonska and colleagues point towards IFN- as a potential 
N1 promoting cytokine (Jablonska et al., 2010). Nevertheless, neutrophils express also 
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receptors for other cytokines that could probably interfere with their polarization. For 
instance IL-10 as anti-inflammatory mediator (Moore et al., 2001), or IL-1 and TNF- 
(Ferrante, 1992) could be involved in N1/N2 modulation. Thus, under tumor conditions IL-
10 inhibits the secretion of pro-inflammatory IL-1 and TNF- by TANs (Ferrante, 1992). 
Extrapolating these findings, the complex composition of pro- and anti-inflammatory 
mediators in the tumor microenvironment gradually shapes the immune phenotype of TAN 
and thus influences tumor promotion.  
2.2.6. Neutrophils as type I IFN effector cells 
Under certain inflammatory and infectious conditions neutrophils were identified as cells that 
produce type I IFNs and respond to them, retaining an effector phenotype. As such, 
neutrophils produce considerable amounts of IFN- in the autoimmune disease systemic 
Lupus erythematosus (SLE) (Decker, 2011). In addition, type I IFNs have been demonstrated 
to induce the formation of NETs, further exacerbating SLE pathogenesis (Knight and Kaplan, 
2012). Under infectious conditions neutrophil recruitment and activation seem to be 
influenced by type I IFNs. As consequence, in MyD88
-/-
 animals with altered type I IFN 
responses neutrophil recruitment and activation were significantly reduced upon infection 
with Burkholderia pseudomallei leading to enhanced liver damage and death of the 
respective mice (Wiersinga et al., 2008). Moreover, in a model of septic shock, type I IFNs 
were shown to interfere with neutrophil recruitment and pharmacological inhibition of type I 
IFN signaling was able to block the onset of sepsis (Dejager et al., 2014) 
Of note, type I IFNs also seem to exert important effects on neutrophils under tumor 
conditions. In absence of endogenous IFN- infiltration of neutrophils into the tumor was 
significantly enhanced thus resulting in notably faster tumor growth of transplantable 
MCA205 fibro sarcoma and B16F10 melanoma (Jablonska et al., 2013). Moreover, 
endogenous IFN- seems to inhibit the expression of VEGF and MMP9 by neutrophils, 
thereby interfering with tumor angiogenesis and development (Jablonska et al., 2010). 
Interestingly, neutrophil accumulation and function seem to be controlled by endogenous 
IFN-not onlyin the primary tumor. In fact, also the setup of a pre-metastatic niche in the 
lung of spontaneously metastasizing 4T1 mammary tumor bearing mice is boosted in the 
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absence of endogenous IFN- independently of tumor size, thus facilitating a significantly 
faster formation of metastasis (Wu & Andzinski et al. 2014, submitted).  
2.2.7. Coherency of TAN and myeloid derived suppressor cells  
One property of an invasive malignancy is the establishment of a permissive 
microenvironment allowing progression and metastasis. As already explained in section 2.2.4 
and 2.2.5., neutrophilic granulocytes are an important component in this scenario. Besides 
neutrophils, also myeloid precursor cells, the so called MDSCs, accumulate in the tumor 
bearing host and contribute to tumor progression (Gabrilovich et al., 2012a). MDSCs consist 
of a mixture of immature myeloid cells belonging to either the mononuclear (Mo-MDSCs) or 
polymorphonuclear (G-MDSCs) subgroup. The minimal immunophenotypic description of 
Mo-MDSCs is the co-expression of CD11b and Ly6C, meanwhile G-MDSCs can be 
characterized by surface expression of CD11b and Ly6G. Importantly, common feature of all 
MDSCs is their immunosuppressive functionality, carried out via different mechanisms 
including the production of arginase I (Brandau et al., 2013). Thus, MDSCs have been 
described to inhibit activation and proliferation of both CD8
+
 as well as CD4
+
 T cells (Bronte 
et al., 2000; Mazzoni et al., 2002). This process can be antigen-specific or unspecific 
(Nagaraj et al., 2007; Sinha et al., 2005). In addition, MDSCs were demonstrated to induce 
Tregs and M2 polarization of macrophages via the secretion of IL-10 and TGF- (Sinha et 
al., 2007; Huang et al., 2006). Whether they also suppress NK cells is a matter of 
controversial discussion and most probably depends on the subset of MDSCs (Ostrand-
Rosenberg and Sinha, 2009). Interestingly, MDSC accumulation seems not to be restricted to 
tumor situations, but can also be observed in response to bacterial infections (Delano et al., 
2007), autoimmunity (Zhu et al., 2007) or stress (Jin et al., 2013; Kokolus et al., 2013). In 
general, the induction of MDSC accumulation is manly driven by pro-inflammatory 
mediators such as IL-1 or IL-6 (Bunt et al., 2007, 2006) and angiogenic factors like VEGF 
(Gabrilovich et al., 1998). 
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Figure 2.11. Potential differentiation pathways of TAN and granulocytic MDSCs. It is still 
under debate whether MDSCs differentiate from progenitor cells or mature granulocytes 
(Brandau et al., 2013). 
To distinguish TAN and G-MDSCs is difficult. A clear cut definition of both cell subsets is 
currently missing. Indeed, there appears to be a significant overlap of TAN and G-MDSC 
functionality in the tumor-bearing host notwithstanding certain differences between the 
populations (Brandau et al., 2013). Just recently, large-scale gene expression analysis of G-
MDSCs, naive neutrophils and TAN gave a first hint suggesting that G-MDSCs share more 
common features with naïve neutrophils than TAN. Nevertheless, in this study the different 
populations were isolated from different organs, clearly diminishing the impact of the 
reported findings (Fridlender et al., 2012). In the human system, only two studies report 
differences between G-MDSCs and TAN. In renal cell carcinoma, G-MDSCs secreted high 
amounts of arginase I while TAN did not (Rodriguez et al., 2009). In head and neck cancer, 
respectively, G-MDSCs showed decreased migratory capacities and LPS-induced IL-8 
secretion (Brandau et al., 2011). However, the differentiation pathways of G-MDSCs vs. 
TAN (Fig.2.11) are elusive to date. While one theory suggests the independent development 
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of TAN and G-MDSCs from progenitor cells (Gabrilovich et al., 2012b), others describe G-
MDSCs as neutrophil phenotype developing from mature granulocytes characterized by 
immunosuppressive functions. TAN on the other hand are characterized by direct tumor 
promoting capacity (Pillay et al., 2013). All facts considered, in this thesis TANs are defined 
as Gr1
hi
/Ly6G
+
/Ly6C
int
/CD11b
+
/F4/80
int
 cells with a neutrophilic nuclear morphology and a 
lack of T cell suppressive functions. 
2.2.8. TAN as target for tumor therapy 
Priming of TANs towards a tumor-toxic N1 phenotype or depletion of N2 tumor-promoting 
neutrophils from the tumor bearing patients would be highly desirable aims for novel cancer 
immunotherapies. In general, two major strategies could be applied for this issue. On the one 
hand, targeting the CXCL8/CXCR2 axis could completely deplete TAN. However, also the 
N1 fraction would be reduced. On the other hand, certain TAN derived tumor-promoting 
factors could be targeted directly or TAN could be pharmacologically reprogrammed to 
develop anti-tumor functions (Gregory and Houghton, 2011). Indeed, concerning the 
interference with TAN migration, the current focus is on the development of receptor 
antagonists for CXCR2 (Walters et al., 2008). Another promising strategy is the specific 
inhibition of TAN derived neutrophil elastase that was shown to significantly retard tumor 
progression in mice (Houghton et al., 2010). Similarly, anti-angiogenic therapies that target 
neutrophil derived factors such as MMP9 are promising, especially in the light of the recently 
observed unfavorable outcomes of direct VEGF/VEGFR targeting (Quigley and Deryugina, 
2012). Regarding neutrophil polarization into an N1 phenotype, the application of TGF- 
blocking agents could be very efficient (Fridlender et al., 2009). In fact, this strategy has 
already reached the practical application as the TGF-2 inhibitor AP12009 is in clinical trials 
for the treatment of glioblastoma (Hau et al., 2007). Moreover photodynamic therapy was 
demonstrated to induce the influx of immunostimulatory N1 neutrophils in mice (Kousis et 
al., 2007) and the efficacy of oncolytic viral infections seems to be boosted by the 
recruitment of neutrophils into tumors (Piccard et al., 2012). Additionally, neutrophils 
express the Fc receptors CD16 as well as CD32 and therefore display potential effector cells 
for antibody-dependent tumor cell lysis (Brandau et al., 2012). Interestingly, also the 
therapeutic effect of microbial compounds and biologics seems to be partly due to neutrophil 
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activation (Suttmann et al., 2006; Kandasamy et al., 2011). In summary, targeting TAN 
populations to improve cancer immunotherapy is a promising approach again highlighting 
the importance of further investigating TAN biology. 
2.3. Aim of the work 
Investigation of neutrophil polarization under tumor conditions and therapeutic intervention 
in this process gained increasing attention during the last years. Previous results suggest that 
the type I IFN family member IFN- is of special importance regarding this issue. As 
described above, IFN- was demonstrated to regulate neutrophil attraction (Jablonska et al., 
2013) and pro-angiogenic capacity during tumor development, massively influencing tumor 
progression (Jablonska et al., 2010) and metastasis (Wu & Andzinski, 2014, under review). 
Therefore, it is of major interest to further elucidate the interplay of neutrophils and IFN- in 
the tumor context, which was the central aim of this work. To this end, the nature of type I 
IFN signaling in tumors was characterized. More precisely, it was addressed whether 
constitutive IFN expression is responsible for neutrophil polarization at tumor site or whether 
IFN- is induced by tumor or host derived factors. For this purpose, type I IFN induction in 
different transplantable tumor models was analyzed in vivo using an IFN- reporter mouse 
approach. Furthermore, the potential pathways and cell types responsible for IFN- induction 
and production were defined in vivo by the application of tissue specific conditional IFN- 
reporter mice. Moreover, combinations of knock out mutants for different IFN induction 
pathways were used.  
To generate a better understanding of IFN- impact on the life span and polarization of 
TANs, detailed immunophenotypic characterization studies for N1/N2 TAN markers and 
their functional capacities were performed. In addition, turn over, maturation and apoptosis 
of neutrophils in tumor bearing IFN- sufficient and deficient mice were assessed to create a 
broad overview of IFN- mediated effects on neutrophilic granulocytes.  
The effects of type I IFN tumor therapy are not fully understood to date. To this end the 
translational aspect of this work aimed to investigate the influence of type I IFN therapy on 
the neutrophil phenotype of mice using IFN- treated tumor bearing wild type mice in 
comparison to untreated controls.  
Introduction 
29 
 
Taken together, the present work generates a deeper understanding of type I IFN-driven 
neutrophil polarization in the context of tumors. This should help to develop novel cancer 
immunotherapies targeting the neutrophil/type I IFN axis.
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3. Material and Methods 
3.1. Materials 
3.1.1 Animals 
All experiments performed in wild type animals were conducted using 8 to 12 week old 
female BALB/c (Harlan) or C57BL/6 (HZI breeding) mice. The transgenic animals used in 
the present work were bred in the animal facility of the Helmholtz Center for Infection 
Research (Braunschweig, Germany). Ifnb1
-/-
, Rag2
-/-
, Rag2
-/-
xIfnb1
-/-
, IFN-+/-luc, IFN-
+/flox x Tie2 cre, IFN-+/flox x LysM cre, IFN-+/flox x CD11c cre, IFN-+/flox x CD4 cre, IFN-
+/flox x CD19 cre or STINGgt mice employed in the present studies were backcrossed onto 
the C57BL/6 or BALB/c background for >15 generations All mice were kept under specific 
pathogen free (SPF) conditions. The studies have been reviewed and approved by an ethic 
committee of the regulatory authorities LAVES of Lower Saxony (33.9-42502-04-13/1122 
permission number). 
3.1.2 Cell lines 
All tumor cell lines used in the present work were cultivated in Iscove’s Modified Dulbecco’s 
Medium (IMDM) (Gibco BRL; Invitrogen) supplemented with 10% (v/v) heat-inactivated 
fetal calf serum (FCS) (Integro), 250µmol/l β-mercaptoethanol (Serva), and 1% (v/v) 
penicillin/streptomycin (Sigma-Aldrich).
 
Cells were
 
grown in monolayer at 37°C in a 
humidified CO2 incubator. B16F10 (C57BL/6), MCA205 (C57BL/6), LLC1 (C57BL/6), 4T1 
(BALB/c) or CT26 (BALB/c) tumor cells were used in all experiments. 
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3.1.3 Antibodies 
To perform flow cytometric analysis of single cell suspensions from bone marrow, blood, 
spleen, lung or tumor following antibodies were used: 
Specificity Clone Fluorochrome Company 
CD16/32 2.4G2 none BD Pharmingen 
CD11b M1/70 PE or APC eBioscience 
Gr1 RB6-8C5 PE-Cy7 or AlexaFluor 647 eBioscience 
Ly6G 1A8 PE-Cy7 or AlexaFluor 647 Biolegend 
Ly6C AL-21 Alexa700 BD Pharmingen 
Fas 15A7 PE eBioscience 
Active Caspase 3 C92-605 PE BD Pharmingen 
TNF- MP6-XT22 FITC eBioscience 
F4/80 BM8 PerCP-Cy5.5 eBioscience 
ICAM1 YN1/1.7.4. PE eBioscience 
CD45 30-F11 APC-Cy7 Biolegend 
CD62L MEL-14 APC eBioscience 
CD80 16-10A1 PE eBioscience 
CD86 GL1 FITC BD Pharmingen 
Arginase I  APC R&D Systems 
 
3.1.4 Primer 
Real-Time RT-PCRs were performed with the following primers: 
Bax: (s) 5´- ATG CGT CCA CCA AGA AGC TGA G-3´; (as) 5´- CCC CAG TTG AAG 
TTG CCA TCA G-3´ 
BCL-xL: (s) 5´- GGC TGG GAC ACT TTT GTG GAT-3´; (as) 5´- AAG CGC TCC TGG 
CCT TTC-3´ 
Caspase 3: (s) 5´- ATG GGA GCA AGT CAG TGG AC-3´; (as) 5´- TTG AGG TAG CTG 
CAC TGT GG-3´ 
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mG-CSF: (s) 5´-CCA GAG GCG CAT GAA GCT AAT -3´; (as) 5´-CGG CCT CTC GTC 
CTG ACC AT-3´ 
Caspase 8: (s) 5´-TGC TTG GAC TAC ATC CCA CAC-3´; (as) 5´-TGC AGT CTA GGA 
AGT TGA CCA-3’ 
Apaf1: (s) 5’- CAG TAA TGG CGT CTT GTC AGT-3’; (as) 5´- AAG CGG CTG CTC GTT 
GAT ATT -3´ 
cFLIP: (s) 5´- GCT CCA GAA TGG GCG AAG TAA -3´; (as) 5´- ACG GAT GTG CGG 
AGG TAA AAA-3´ 
IFNb1: (s) 5´- CTG GCT TCC ATC ATG AAC AA-3´; (as) 5´- CAT TTC CGA ATG TTC 
GTC CT-3´ 
To standardize the cDNA the house keeping gene Rps9 was tested with primer pairs: 
(s) 5’-TTG ACG CTA GAC GAG AAG GAT-3’; (as) 5’-AAT CCA GCT TCA TCT TGC 
CCT-3’.  
3.2 Methods 
3.2.1 Murine tumor models 
Exponentially
 
growing tumor cells were harvested using 0.05% trypsin, washed,
 
and 
suspended in LPS-free PBS. Tumors were initiated by subcutaneous (s.c) injection of
 
5x10
5
 
cells in 100µl PBS. Tumor sizes were evaluated by caliper. All analytical experiments were 
done 12-14 days after initiation. The volume of a tumor was calculated using the formula: V 
= 4/3 * π * (h * w 2) / 8 (h = height and w = width). It was assumed that depth and width of 
the tumor are equal. 
3.2.2 Low dose IFN- therapy of tumor bearing mice 
C57BL/6 or BALB/c mice were inoculated with B16F10 or 4T1 tumors. From day 3 after 
inoculation onwards they received i.v. treatment with 1000IU rmIFN-every other day. 
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After two weeks the mice were sacrificed and single cell suspensions from blood, tumor and 
lung were analyzed by flow cytometry. 
3.2.3 Flow cytometry of cells from tumor, lung, blood, bone marrow and spleen 
To assess the immunological phenotype of neutrophil granulocytes from different tissues, 
single cell suspensions of blood, tumor, lung, spleen and bone marrow were analyzed by flow 
cytometry. Therefore, non-necrotic tumor tissue was cut into 1-2mm
3
 pieces. The pieces were 
rinsed twice with PBS and digested using dispase/collagenaseA/DNase suspension in IMDM 
(0.2mg/ml 0.2mg/ml 100mg/ml) for 45min in 37°C. Cell suspensions were meshed through 
50µm disposable filters (Cell Trics, Partec). Subsequently, erythrocytes were removed using 
erythrocyte lysis buffer (ACK buffer). To prepare single cell suspensions from lung tissue, 
the lungs were first perfused through the right heart chamber using 2 to 4ml cold PBS. 
Afterwards they were cut into small pieces, digested for 60min and treated as described 
above. Similarly, blood and bone marrow cell suspensions were treated with ACK buffer. To 
avoid unspecific binding of the conjugated antibodies single cell suspensions were treated 
with anti-mouse CD16/CD32 Fc block for ten minutes on ice. Then, cells were stained for 10 
min in FACS buffer (PBS, 2%FCS, 0,5mM EDTA) with the conjugated antibodies listed 
above. To assess the expression of intracellular proteins the cells were subsequently fixed and 
permeabilized using BD
TM 
Cytofix-Cytoperm buffer for 20 min at room temperature in the 
dark. Afterwards, intracellular markers were stained with flurochrome-conjugated antibodies 
and flow cytometry was performed using the BD LSRII system (BD Bioscience). Data were 
analyzed by BD FACSDiva software (BD Bioscience). 
3.2.4 Fluorescence activated cell sorting of neutrophils and DCs 
Single cell suspensions from the different tissues were prepared and stained as described 
before. CD11b
+
Gr1
high
 or CD11b
+
Ly6G
+
 neutrophils as well as CD11c
+
CD11b
+ 
myeloid DCs 
or CD11c
+
CD11b
- 
conventional DCs were sorted using a FACSAria
TM
 cell sorter (BD 
Bioscience) and the purity of cells was proved by reanalysis.  
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3.2.5 BrdU labeling of bone marrow cells and FACS detection 
To quantify neutrophil turnover, tumor bearing C57BL/6 as well as syngeneic Ifnb1
-/-
 mice 
were challenged with B16F10 melanoma and i.v. injected with 1 mg BrdU on day 7 after 
tumor inoculation. 24, 48, 72, 96, 120, 144 and 168 hours later blood was taken from the 
mice via retro-bulbar punktion. After erythrocyte lysis (ACK buffer) the cells were stained 
for Ly6G and CD11b. Subsequently, BrdU was stained using BD BrdU Flow Kit (BD 
Bioscience) according to the manufacturers protocol and BrdU
+
 neutrophilic granulocytes 
were detected via flow cytometry. 
3.2.6 Detection of reactive oxygen species via FACS 
To detect the cellular ROS content, single cell suspensions of blood and tumor of C57BL/6 
and syngeneic Ifnb1
-/-
 mice were prepared as described above for flow cytometric analysis. 
Neutrophils were stained, resuspended in 200 µl RPMI (≤ 1x106 cells per well) containing 20 
µM DCFDA and incubated for 1 hour at 37° in the dark. Subsequently, the cells were 
analyzed by flow cytometry without prior washing. 
3.2.7 Flow cytometric analysis of cytochrome c 
To detect mitochondrial cytochrome c release in apoptotic cells the InnoCyte
TM
 Flow 
Cytometric Cytochrome c Relaese Kit (Calbiochem) was used according to the 
manufacturer’s protocol. 
3.2.8 Detection of caspase 9 activity via flow cytometry 
To analyze the activity of the initiator caspase 9 FAM-FLICA
TM
 Caspase Detection Kit 
(ImmonoChemistry Technologies) was used according to the manufacturers protocol. 
3.2.9 Ex vivo apoptosis assay 
To assess the ex vivo life span of neutrophil granulocytes derived from blood and tumors, 
single cell suspensions were stained as described before. CD11b
+
 Gr1
+
 neutrophils were 
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sorted and distributed in a concentration of 1x10
5
 cells per ml on a 96-well cell-culture dish. 
Cells were then incubated for 18 hours in RPMI containing 10% FCS at 37°C with or without 
the addition of 100 µM Apocyanin, 50 mM Taurine or 5 units/ml rmIFN-β. Subsequently, 
cells were stained with propidium iodid/AnnexinV and analyzed by flow cytometry. 
3.2.10 Ex vivo tumor killing assay 
To assess the ex vivo killing capacity of neutrophil granulocytes derived from blood and 
tumors, single cell suspensions were stained. CD11b
+
 Gr1
+
 neutrophils were sorted and 
distributed on a 96-well cell-culture dish. 20.000 neutrophils were co-cultivated overnight in 
RPMI (10% FCS, 1% (v/v) penicillin/streptomycin) with 10.000 Luciferase-expressing 4T1 
cells to obtain an effector-target-ratio of 2:1. Subsequently, substrate solution (Luciferin 
Calipers) was added to each well and luciferase activity was directly measured in the IVIS 
200 system (Calipers). The emitted light can be correlated to the number of living tumor cells 
per well. 
3.2.11 T cell proliferation assay 
25.000 CD4
+
CD25
-
 responder T cells (T conv) from wild type BALB/c mice were co-
cultured in different ratios with either CD4
+
CD25
+
 regulator T cells (T reg) derived from 
wild type BALB/c mice, or sorted neutrophils from blood or tumors of wild type or Ifnb1
-/-
 
mice in the presence of 200.000 irradiated BALB/c spleenocytes. The cells were kept in 96 
well round-bottom plates in IMDM + 10% FBS. T cells were stimulated with 1µg/ml soluble 
anti-CD3 (clone:145-2C11) for 72h at 37°C 5% CO2. In the last 8-12h of culture proliferating 
T cells were pulsed with 1 µCi 
3
H-thymidine to assess the proliferation rate. 
3.2.12 In vitro treatment with rmIFN-β and RNA isolation 
Sorted cells were cultured in microtiter plates at 1x10
4
 cells/well in 200µl RPMI and rmIFN-
β was added at a concentration of 5 units/ml. After 4h of incubation, cells were harvested and 
total RNA was extracted using the RNeasy Kit (Qiagen) according to the manufacturer’s 
protocol. DNA contamination was eliminated by incubation with DNaseI (Amersham 
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Pharmacia Biotech) and cDNA was prepared using RevertAid First Strand cDNA Synthesis 
Kit (Fermentas) and oligo(dT) as primers.  
3.2.13 PCR and quantitative real time PCR (qRT-PCR) 
To investigate the expression of genes relevant for neutrophil apoptosis or priming, qRT-
PCR was performed using Power SYBR Green Master Mix (Applied Biosystems) and 
analyzed on a 7500 Real Time PCR System (Applied Biosystems). 
PCR was performed with TrueStart TaqDNA Polymerase (Fermentas). 
3.2.14 G-CSF detection via ELISA 
Serum samples of tumor-bearing wild type and syngeneic Ifnb1
-/-
 mice were collected on day 
14 after tumor inoculation and kept at -80°C until the RayBio® Mouse G-CSF ELISA was 
used according to the manufacturer’s description. 
3.2.15 Western blot analysis 
For preparation of cell extracts, tumor tissue was lysed using tissue homogenizer FastPrep-24 
(MP) in buffer containing 250 mM Tris, 0.5% Triton X-100, and Halt protease inhibitor 
cocktail (Thermo Scientific). The following primary antibodies were used: anti-Phospho-
PI3K p85 (Tyr458)/p55 (Tyr199) (Cell Signaling) and anti-Actin (MAB 1501R Chemicon). 
HRP–conjugated anti-rabbit and anti-mouse Abs (Amersham) were used as secondary Abs 
using ECL detection (Bio-Rad). The chemiluminescence signal was recorded digitally by a 
ChemiDoc DRS imaging system (Bio-Rad). Digital signal acquisition and analysis were 
performed using Quantity One Program, Version 4.6 (Bio-Rad). 
3.2.16 Detection of luciferase activity in and ex vivo 
For the determination of the enzymatic activity of luciferase, cells were lysed in Reporter 
Lysis Buffer (Promega). For luciferase activity assays from tissue, weight of tissue fragments 
was determined and fragments were homogenized in proportional volumes of Reporter Lysis 
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Buffer. Lysates were mixed with LARII (Promega) and measured in a luminometer. For in 
vivo imaging, mice were injected i.v. with 150 mg/kg of D-luciferin in PBS (Calipers), 
anesthetized using Isofluran (Baxter) and monitored using an IVIS 200 imaging system 
(Calipers). Photon flux was quantified using the Living Image 3.0 software (Calipers). 
3.2.17 Cytospin analysis 
To quantify the percentage of immature neutrophils derived from blood of tumor bearing 
C57BL/6 mice and syngeneic Ifnb1
-/-
 animals, cytospin analysis of sorted Gr1
+
 CD11b
+
 
neutrophils were performed. After centrifugation (10 min, 800 rpm, 4°C) of 100.000 cells on 
Superfrost
TM
 slides (Thermo Scientific) they were dried and stained with Giemsa solution 
(Sigma Aldrich) for 15 min. Cells were fixed with ice cold methanol for 5 min and covered 
with Neomount
®
 (Merck Millipore). Nuclear morphology was assessed by light microscopy 
(Zeiss) using 20x magnification. For each pooled sample at least 10 fields of view were 
counted and percentage of immature ring shaped nuclei was calculated from total neutrophils. 
3.2.18 Statistics 
Statistical analyses were performed using either unpaired students t test or one-way ANOVA 
in combination with Turkey post-test. Significances were defined according to a 95% 
confidence interval. 
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4. Results 
4.1. Induction and production of IFN- at tumor site 
An influence of endogenous type I IFN signaling on growth and progression of different 
tumor entities has been described in mice and men (Jablonska et al., 2010; Swann et al., 
2007; Deonarain et al., 2003; Picaud et al., 2002; Sgorbissa et al., 2011). Nevertheless, it is 
still unclear to date whether constitutively expressed low amounts of IFN-(Gough et al., 
2012; Lienenklaus et al., 2009; Taniguchi and Takaoka, 2001) or induced type I IFN 
responses are responsible for this phenomenon. Moreover, the type I IFN producing cell 
population(s) as well as potentially inducing ligands in the tumor are currently speculative 
(Fuertes et al. 2013). To this end, the present work addressed these issues in vivo using a 
reporter mouse approach. 
4.1.1. IFN- is induced in different transplantable tumor models on both BALB/c 
and C57BL/6 background 
Type I IFNs such as IFN- can be induced by a broad variety of factors under infectious as 
well as inflammatory conditions. These cytokines are produced and sensed by virtually all 
types of cells (Ivashkiv & Donlin 2013). Applying a previously described IFN- reporter 
mouse model, which allows spatial and temporal resolution of IFN- induction in vivo using 
firefly luciferase as reporter protein (Lienenklaus et al. 2009), the question of IFN- 
induction during tumor development was addressed. To this end, 4T1 mammary carcinoma, 
CT26 colon carcinoma, MCA205 fibro sarcoma or LLC1 lung carcinoma cells were 
subcutaneously (s.c.) injected into the back of syngeneic IFN- reporter mice, respectively. 
Imaging kinetics for a follow up period of 14 days were performed in vivo (Figure 4.1). 
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Figure 4.1. IFN- induction in transplantable murine tumors. Transplantable 4T1 (A), CT26 
(B), MCA205 (C) or LLC1 (D) tumor cells were s.c. injected into the back of IFN- reporter mice 
on BALB/c or C57BL/6 background, respectively. Reporter activity was assessed after 24 hours 
and subsequently every other day, using an IVIS 200 imaging system. Depicted are the results 
obtained 24 hours, 72 hours and 14 days after tumor inoculation. 
24 h after tumor injection an initial signal was detected at the inoculation site. This was true 
for all tested tumor models on both, BALB/c as well as C57BL/6 background. Expectedly, 
the signal was absent in PBS-injected control mice (Data not shown). By 72 hours after cell 
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injection, the signal was around constitutive background levels. At that time, no visible tumor 
could be found for any of the different tumor models. As soon as the tumor started to be 
palpable, the signal reappeared. On day 14 after inoculation the tumors were well established 
and the reporter signal reached levels observed 24 hours after injection indicating a type I 
IFN response in the growing tumors. 
To verify and quantify the IFN- induction in the different tumor models, reporter mice were 
challenged with MAC205 or CT26 tumor cells, respectively. On day 14 after tumor 
inoculation, the mice were sacrificed and tissue homogenates of tumor, spleen and thymus 
were tested for their ex vivo luciferase enzymatic activity indicating IFN- induction (Fig. 
4.2.).  
 
Figure 4.2. Ex vivo luciferase assay comparing IFN- induction in different tumor models 
and different organs. On day 14 after s.c. inoculation of MCA205 or CT26 tumor cells into the 
back of IFN- reporter mice on C57BL/6 or BALB/c background, reporter activity was assessed 
ex vivo using a luminometer to detect luciferase mediated bio luminescence in homogenates 
from tumor tissue, spleen or thymus. The relative luciferase units (RLU) were normalized on 
tissue weight. 
Indeed, the luciferase signal detected in the tumor samples of MCA205 and CT26 tumors 
was significantly higher, compared to spleen, and reached at least the intensity of the thymic 
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IFN- reporter activity. It was demonstrated previously that under steady state conditions, the 
thymus displays the highest constitutive IFN- expression (Lienenklaus et al. 2009). In 
subsequent experiments, MCA205 was used as tumor model system since it induces high 
levels of IFN and is of appropriate genetic background.  
4.1.2. Tie2+ LysM+ CD11c+ DCs produce IFN- at tumor site 
DCs are the major source of type I IFNs in many settings. They have been demonstrated to 
produce IFN- in tumor draining lymph nodes where they are involved in cross-priming of 
tumor antigen-specific CD8
+
 T cells (Fuertes et al. 2011). Since it is not known whether DCs 
are also responsible for type I IFN production directly in the tumor, the present work tried to 
define the cellular source of the induced IFN- in MCA205 fibro sarcoma. In a first 
experiment, the contribution of host cells and transplanted tumor cells was addressed. 
Therefore, C57BL/6 and syngeneic IFN-flox/flox mice were inoculated s.c. with MCA205 
cells. On day 14 after tumor injection the mice were sacrificed and RNA from total tumor 
tissue was isolated. After reverse transcription, PCR was performed to analyze IFN- gene 
expression. In wild type mice as well as in tumor cells, the respective PCR product is 183 bp 
in size. IFN-flox/flox mice (BLLB6) carry a loxP site in the 5’-UTR of the IFN- locus. 
Therefore, the resulting PCR product has a size of 221 bp allowing to distinguish the signal 
derived from host vs. tumor cells. As depicted in figure 4.3. (A), both, host as well as tumor 
cells express IFN- in vivo. Interestingly, MCA205 tumor cells did not produce detectable 
amounts of IFN- in cell culture (Fig. 4.3. B). As control, also Ifnb1 expression in total 
MCA205 tumor tissue was analyzed by qRT-PCR ex vivo (Fig. 4.3. B.). Importantly, this 
sample also contains host cells and does therefore not allow to distinguish the respective 
signal source.  
To further characterize the host cell population responsible for IFN- production at tumor 
site, specific conditional reporter mice were used. In these mice, the IFN- coding sequence 
is replaced by the reporter luciferase upon cell specific Cre recombinase expression 
(Lienenklaus et al. 2009; Solodova et al. 2011). In the present work, Tie2Cre, CD19Cre, 
CD4Cre, LysMCre and CD11cCre were applied to detect IFN- production from 
hematopoietic and endothelial cells, B cells, T cells, myeloid cells or DCs. The results 
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obtained from ex vivo luciferase measurements on day 14 after tumor inoculation are 
depicted in figure 4.4. 
 
Figure 4.3. Host and tumor cells produce IFN- in vivo. On day 14 after s.c. inoculation of 
MCA205 fibro sarcoma into C57BL/6 and syngeneic BLL/B6 (IFN-flox/flox) animals, total RNA 
from tumor tissue was harvested. After reverse transcription PCR analysis of IFN- gene 
expression was performed (A) to distinguish host and tumor cell expression of IFN-. In 
addition, qRT-PCR analysis of IFN- gene expression were performed using MCA205 cells from 
cell culture (B). 
For tumor homogenates of Tie2Cre, LysMCre and CD11cCre conditional IFN- reporter 
mice, 100% equivalent signal intensity to the global reporter animals could be detected (Fig. 
4.4. A to C). This indicates that first of all a cell population derived from hematopoietic 
precursor cells expressing Tie2 is responsible for IFN- production at tumor site. In addition, 
the producing cells apparently express the myeloid lineage marker LysM and the integrin 
CD11c or expressed them during their ontogeny. Moreover, a subpopulation (~2%) of tumor 
associated host cells producing IFN- in murine fibro sarcomas has expressed or still 
expresses CD4 (Fig. 4.4.D). Of note, no signal could be detected in CD19Cre reporter mice 
(Fig. 4.4.E), indicating that tumor infiltrating B cells do not contribute to IFN- production in 
this experimental setting. 
Results 
43 
 
 
Figure 4.4. Phenotypic characterization of IFN- producing tumor associated host cells. 
To assess the cellular source of IFN- in tumors, IFN- reporter mice as well as conditional 
Tie2Cre (A), LysMCre (B), CD11cCre (C), CD4Cre (D) and CD19Cre (E) reporter animals were 
injected with MCA205 cells. After 14 days the mice were sacrificed and ex vivo luciferase 
measurement was performed. The experiments were repeated at least once and statistical 
significance was calculated using unpaired students t test (** p ≤ 0,005, *** p ≤ 0,0005).  
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As murine DCs belong to the hematopoietic compartment, can be derived from myeloid 
precursor cells and express CD11c, they very likely are the cellular source of type I IFN 
under tumor conditions.  
To validate this hypothesis, DCs populations from spleen and tumor of C57BL/6 mice were 
sorted and tested for gene expression of IFN- (Fig.4.5.). By using splenic DC populations 
and CD19
+
 B cells as control, it could be demonstrated that tumor associated DC populations 
express comparably high amounts of IFN-. Thus, the data presented here provide strong 
evidence that myeloid dendritic cells are the major cellular source of IFN- in solid tumors.  
 
 
Figure 4.5. Tumor infiltrating DCs express IFN-. To validate tumor infiltrating DCs as 
cellular source of IFN- in the tumor microenvironment C57BL/6 mice were injected s.c. with 
MCA205 fibro sarcoma cells. On day 14 after tumor inoculation the mice were sacrificed and 
single cell suspensions from spleen and tumor prepared. CD11c+/CD11b- cDC, CD11c+/CD11b+ 
mDCs and CD19+ B cells were sorted using a BD FACS ARIA SORP system, RNA was isolated and 
qRT-PCR analysis for IFN- gene expression were performed. Data represent a mean of at least 
five pooled animals. The experiment was repeated once. 
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4.1.3. Sting signaling is responsible for IFN- induction in solid tumors 
Three different receptor systems are known to induce type I IFNs upon ligand engagement. 
TLRs sense a broad spectrum of PAMPs and DAMPs and signal via the adaptor proteins Trif 
and MyD88 (Noppert et al. 2007). RLRs are cytosolic RNA receptors that signal via the 
adaptor protein Cardif/IPS-1/MAVS to induce type I IFN expression (Loo & Gale 2011) and 
the third receptor system capable to mount type I IFN responses are CDRs. They sense 
cytosolic viral, bacterial or host derived DNA and signal via the mitochondrial resident signal 
transducer Sting (Paludan & Bowie 2013). After integration of all signaling pathways by the 
central kinase TBK-1 type I IFN gene expression is induced by transcription factors of the 
IRF family, namely IRF3, IRF7 or IRF5, alone or in combination (Barnes et al. 2002). 
Regarding IFN induction in the tumor microenvironment, neither the pathways nor the 
ligands responsible for type I IFN induction are identified to date (Fuertes et al. 2013). 
Therefore, the present work aimed to characterize the signaling pathways responsible at 
tumor site. To this end, IFN- reporter mice were bred with mice carrying knockout 
mutations for molecules known to be involved in type I IFN induction. These mice were 
analyzed for their ability to induce IFN- associated with the transplanted tumor. (Fig. 4.6.). 
As demonstrated in Fig. 4.6 neither TLRs (Fig.4.6. A) nor RLRs (Fig.4.6. B) are involved in 
the induction of a type I IFN response in tumors. However, the lack of the adaptor protein 
Sting drastically decreased IFN- gene expression at the tumor site in comparison to wild 
type animals (Fig.4.6. C). 
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Figure 4.6. Identification of the signaling pathways inducing type I IFN expression in 
tumors. To identify the receptor system and transcription factors involved in IFN- induction 
under tumor conditions, a combination of knockout mutants for the respective proteins and the 
IFN- reporter mouse approach was used. Therefore, MCA205 fibro sarcoma were inoculated 
s.c. into the back of global reporter and reporter animals deficient for the TLR adaptor proteins 
Trif and MyD88 (A) or the RLR adaptor protein Cardif (B). On day 14 after tumor cell injection 
the mice were sacrificed and ex vivo luciferase measurement was performed for tumor 
homogenates. The role of CDR signaling in type I IFN induction was assessed using qRT-PCR for 
IFN- gene expression in total tumor tissue of C57BL/6 wild type mice or Sting-/- animals.(C). 
The data represent a mean of at least 4 animals per group. The experiments were repeated at 
least once and statistical significance was calculated using unpaired students t test or one way 
ANOVA with turkey post-test (*p≤0,05). 
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Figure 4.7. Identifikation of the signaling pathways inducing type I IFN expression in 
tumors. To identify the receptor system and transcription factors involved in IFN- induction 
under tumor conditions a combination of knockout mutants for the respective proteins and the 
IFN- reporter mouse approach was used in the present work. Therefore, MCA205 fibro 
sarcoma were inoculated s.c. into the back of global reporter animals and reporter animals 
deficient for or the IRF family members IRF3, IRF7 (A) or IRF5 (B). The data represent a mean 
of at least 4 animals per group. The experiments were repeated at least once and statistical 
significances were calculated using unpaired students t test or one way ANOVA with turkey 
post-test (*p≤0,05). 
Regarding the IRF transcription factors, the absence of IRF7 did not alter the bio luminescent 
signal ex vivo, (Fig.4.7. A). The lack of IRF3 on the other hand reduced the signal drastically. 
However, the signal was not completely abolished upon IRF3 deficiency, suggesting that 
additional transcription factors can independently of IRF3 induce IFN- gene expression. 
Indeed, IRF5 deficiency significantly decreased the reporter signal and therefore seems to be 
involved in IFN- induction under tumor conditions (Fig.4.7. B). 
Taken together these results demonstrate that type I IFN induction in solid tumors depends on 
the adaptor protein Sting and the transcription factors IRF3 and IRF5. 
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4.2. Influences of endogenous IFN- on life span and cell death of TAN 
As already described in previous studies, endogenous type I IFNs influence growth, 
angiogenesis and metastasis formation of different transplantable murine tumors via the 
regulation of TAN characteristics and migration (Jablonska et al., 2013, 2010). In addition 
type I IFNs were demonstrated to regulate maturation and apoptosis of various other cell 
subsets including DCs, macrophages and T cells (González-Navajas et al., 2012). 
Interestingly, detailed analysis of type I IFN mediated effects on neutrophil maturation, life 
span and apoptosis under tumor conditions are lacking to date. Therefore, the second part of 
the present work aimed to elucidate the impact of endogenous type I IFNs on the maturation, 
turn over and apoptosis of neutrophilic granulocytes in a tumor setting. 
4.2.1. Endogenous IFN- controls neutrophil turn over and maturation under 
tumor conditions 
Under steady state conditions, neutrophil maturation, turn over and apoptosis are tightly 
regulated and circulation time as well as life span of neutrophilic granulocytes are 
comparably short (Amulic et al., 2012a). Interestingly, under inflammatory conditions these 
features appear to be significantly altered and neutrophil life span can be remarkably 
prolonged (Mayadas et al., 2014; Amulic et al., 2012a; Elbim and Estaquier, 2010). This is 
also true for tumor bearing hosts, where altered neutrophil kinetics can be observed and seem 
to be associated with adverse prognostic outcomes for the patients (Fridlender and Albelda, 
2012). Of note, investigation of the complex regulation underlying neutrophil kinetics under 
tumor conditions is just emerging and little is known about the role of type I IFNs in this 
scenario. Therefore, in the present work neutrophil turn over and maturation under tumor 
conditions were analyzed in mice sufficient or deficient for endogenous IFN-. To this end, 
tumor bearing animals were injected i.v. with BrdU to monitor neutrophil turn over via flow 
cytometry as depicted in figure 4.8. (A). Moreover, the maturation status of circulating blood 
neutrophils was assessed using phenotypic cytospin analysis of sorted blood neutrophils from 
the various mice (Fig.4.8. B to D). 
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Figure 4.8. Altered mobilization and maturation of neutrophilic granulocytes under 
tumor conditions in the absence of endogenous IFN-. To investigate neutrophil turn over in 
presence or absence of endogenous IFN- C57BL/6 and syngeneic Ifnb1-/- mice were challenged 
with B16F10 melanoma. On day 7 after tumor inoculation the mice were i.v. injected with BrdU 
(1 mg) and the occurrence of Gr1+ CD11b+ BrdU+ labeled neutrophils in blood was monitored 
for 7 days via flow cytometry. In addition, neutrophils from blood of the different animals were 
sorted on day 14 after tumor inoculation and cytospin analysis were performed (B). Panels (C) 
and (D) illustrate the representative morphological maturation levels of neutrophils derived from 
blood of WT (C) and syngeneic Ifnb1
-/- 
 (D) tumor bearing mice. The experiment was repeated twice 
with at least 5 mice per group and statistical significance was determined using unpaired students t 
test or two way ANOVA (**p≤0,005). 
Interestingly, in tumor bearing Ifnb1
-/-
 mice, turn over and mobilization of Gr1
+
 CD11b
+
 
BrdU
+
 labeled neutrophils was significantly faster. Furthermore, a higher number of 
neutrophils entered the blood stream under such conditions (Fig.4.8. A). This was most likely 
due to the release of immature neutrophils into circulation in tumor bearing mice deficient for 
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endogenous IFN- Significantly elevated numbers of neutrophils with a ring-shaped nucleus, 
indicative for immature neutrophils, could be detected via cytospin analysis (Fig.4.8. B to D). 
4.2.2. Prolonged life span of neutrophilic granulocytes from IFN- deficient mice 
Neutrophil counts, turn over and maturation in Ifnb1
-/-
 mice are significantly altered, 
compared to wild type control mice (Jablonska et al., 2010). At steady state, the life span of 
neutrophils is short, but increases under pro-inflammatory conditions. Extrapolating these 
data, the life span of TANs might be increased in the absence of IFN-This could be one 
reason for the accumulation of such cells in tumors. To proof this hypothesis, C57BL/6 or 
BALB/c and syngeneic Ifnb1
-/-
 mice were challenged with B16F10 melanoma or 4T1 
mamma carcinoma cells, respectively. To assess their live span, neutrophils from blood and 
tumors were isolated to high purity on day 14 after tumor inoculation and cultivated for 18 
hours ex vivo. Subsequently, the cells were stained with propidium iodide (PI) to distinguish 
live and dead cells (Fig.4.9.). 
As shown in Figure 4.9., neutrophils derived from blood and tumors of IFN- deficient mice 
exhibited a significantly prolonged life span, compared to wild type controls in both tumor 
models (Fig.4.9. A to D). This phenomenon was partly abolished when small amounts of 
rmIFN- were added to the cultures (Fig.4.9. A and B). 
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Figure 4.9. Neutrophil life span is prolonged in the absence of endogenous type I IFN. 
Percentage of living CD11bhi Gr1hi neutrophil granulocytes derived from (A) blood and (B) 
tumor of Ifnb1-/- C57BL/6 mice or (C) blood and (D) tumor of Ifnb1-/- BALB/c mice is increased, 
after 18h in culture ex vivo, in comparison to controls. 4T1 breast carcinoma cells were injected 
s.c. into the mammary fat pad of BALB/c or Ifnb1-/- mice. C57BL/6 mice were injected s.c. on the 
flank with B16F10 melanoma cells. After 14 days mice were sacrificed, total cell suspensions of 
blood and tumor prepared and neutrophils isolated using FACS Aria sorter. Subsequently, cells 
were cultivated ex vivo for 18 hours in RPMI, stained with PI and analyzed using the BD LSR II 
system. Data represent mean ± SEM. (* p ≤ 0.01). 
4.2.3. Decreased Fas expression on neutrophils from tumor bearing Ifnb1-/- mice 
Apoptosis is the predominant pathway of neutrophil cell death and can be induced via death 
receptor signaling (Jonsson et al., 2005). In line with the prolonged life span of neutrophils in 
the absence of endogenous IFN-, decreased expression of Fas on neutrophils derived from 
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tumors (Fig.4.11. B) and lung (Fig.4.11. C) was observed. Blood derived neutrophils showed 
equivalent Fas expression in wild type and Ifnb1
-/-
 mice, suggesting that Fas regulation by 
IFN- takes place after the second transmigration into target tissues (Fig.4.11. A). Similar 
results were obtained for wild type and Ifnb1
-/-
 mice on BALB/c background (Fig.4.10). Of 
note, since the ex vivo life span of blood neutrophils from tumor bearing Ifnb1
-/-
 mice is 
prolonged without a significant upregulation of death receptors (Fig.4.11. A; Fig.4.10 A), 
additional regulatory mechanisms independent of death receptor signaling might be involved. 
 
Figure 4.10. Neutrophil granulocytes from Ifnb1-/- tumor bearing mice show decreased 
expression of Fas independent of the tumor model. 4T1 tumors were inoculated s.c. into the 
mammary fat pad of either BALB/c WT or Ifnb1-/- mice. 14 days after tumor injection the mice 
were sacrificed and single cell suspensions of (A) blood, (B) tumor and (C) lung were prepared 
and analyzed using the BD LSR II system. Depicted is the quantification of Fas expression on 
CD11bhi Gr1hi Ly6C int granulocytes. Three independent experiments were performed, with at 
least 5 mice per group. Statistical significance was determined using unpaired Students t-test 
(** p ≤ 0,005). 
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Figure 4.11. Neutrophil granulocytes from Ifnb1-/- tumor bearing mice show decreased 
expression of Fas after their transmigration into the target tissues. B16F10 tumors were 
inoculated s.c. on the back of either C57BL/6 WT or Ifnb1-/- mice. 14 days after tumor injection 
the mice were sacrificed and single cell suspensions of (A) blood, (B) tumor and (C) lung were 
prepared and analyzed using the BD LSR II system. Depicted are representative FACS plots and 
quantification of Fas expression on CD11bhi Gr1hi Ly6C int granulocytes. Three independent 
experiments were performed, with at least 5 mice per group. Statistical significance was 
determined using unpaired Students t-test (** p ≤ 0,005). 
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4.2.4. Diminished ROS production by neutrophils in the absence of endogenous 
IFN- 
Besides apoptosis induction via cell-cell contact, neutrophils harbor intrinsic activities 
involved in the regulation of this process. Upon stimulation, they produce huge amounts of 
ROS that kill invading microbes (Amulic et al., 2012b). A large body of evidence suggests 
that ROS can also promote neutrophil apoptosis via a not yet defined mechanism (Gabelloni 
et al., 2013). To address whether ROS production is reduced in the absence of IFN- in a 
tumor bearing host and thus influences the neutrophil life span, C57BL/6 and syngeneic 
Ifnb1
-/-
 mice were challenged with B16F10 melanoma cells. Animals were sacrificed 14 days 
after tumor inoculation and single cell suspensions from blood and tumors were tested for 
their content of ROS, using the cell-permeable reagent 2´, 7´-dichlorfluorescein diacetate 
(DCFDA). Interestingly, neutrophils isolated from IFN- deficient mice showed reduced 
ROS production, compared to wild type controls (Fig. 4.12. A and C). This difference was 
especially significant in tumor infiltrating neutrophils (Fig.4.12. C).  
To further confirm the importance of ROS for neutrophil apoptosis, neutrophils from the 
different tissues of C57BL/6 or syngeneic Ifnb1
-/-
 mice were isolated, as described above, and 
incubated for 18 hours in the presence or absence of apocyanin or taurine to inhibit 
generation of ROS. Afterwards, the cells were stained with PI and Annexin V to detect 
apoptotic cells by flow cytometry. Apparently, the NADPH oxidase inhibitor apocyanin 
significantly reduced the apoptosis rate of neutrophils derived from blood (Fig.4.12. B) and 
tumor (Fig.4.12. D) of both types of mice. The same holds true for the ROS scavenger taurin 
in blood derived neutrophils of C57BL/6 mice (Fig.4.12. B). 
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Figure 4.12. Tumor-infiltrating neutrophils produce lower amounts of cytotoxic ROS in 
the absence of endogenous IFN-β. B16F10 melanoma cells were s. c. injected on the back of 
C57BL/6 mice or Ifnb1-/- mice. 14 days after tumor inoculation the mice were sacrificed, single 
cell suspensions of tumors and lungs prepared, and stained for CD11b and Ly6G. Afterwards, 
cells were incubated in RPMI medium containing 20 µM 2´, 7´-dichlorfluorescein diacetate 
(DCFDA). Depicted is the ROS production of blood (A) and tumor (C) derived CD11bhi Ly6G hi 
neutrophil granulocytes. To additionally verify the role of ROS in neutrophil apoptosis, CD11bhi 
Ly6G hi neutrophil granulocytes from blood (B) and tumor (D) were isolated using BD FACS Aria 
for cell sorting. Cells were incubated 18 hours in RPMI with or without the addition of 
apocyanin (100 µM) or taurin (50 mM). Thereafter, the cells were stained with PI and Annexin 
V, and analyzed using the BD LSR II system. Data represent mean ± SEM. (* p ≤ 0.01). 
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4.2.5. IFN- regulates the expression of pro- and anti-apoptotic BCL2 family members 
in tumor- and blood-derived neutrophils 
The intracellular apoptosis pathway is tightly regulated by several members of the Bcl-2 
family. This proteins are characterized by their pro- or anti-apoptotic functions as well as by 
their expression of the Bcl-2 homology domain (García-Sáez, 2012). For neutrophils, the 
expression of the pro-apoptotic Bcl-2 protein Bax and its anti-apoptotic counterpart BCL-xL 
is of special importance (Weinmann et al., 1999; Perskvist et al., 2002).  
To address whether IFN- regulates the expression of such proteins and thus influences 
longevity of neutrophils, CD11b
+
 Gr1
+
 cells from blood and tumors of B16F10 tumor-
bearing mice were sorted and mRNA isolated to perform quantitative Real-Time-PCR (qRT-
PCR). In accordance with increased longevity, tumor infiltrating neutrophils from Ifnb1
-/-
 
mice exhibited a significantly increased BCL-xL expression accompanied by only slightly 
increased Bax expression. In contrast, tumor infiltrating neutrophils from wild type mice 
show the opposite pattern of expression (Fig.4.13. A and B). Pre-incubation of Ifnb1
-/-
 tumor-
infiltrating neutrophils with 5 units of rmIFN-partly restored WT gene expression. 
Additionally, in tumor neutrophils of WT animals the Bax/BCL-xL ratio was highly up-
regulated, compared to Ifnb1
-/-
 mice (Fig.4.13. C). Interestingly, in blood neutrophils 
expression levels as well as Bax/BCL-xL ratio were reduced compared to neutrophils from 
tumors. This is consistent with the idea that mainly tissue resident neutrophils undergo 
apoptosis. 
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Figure 4.13. Bax and BCL-xL gene expression in blood and tumor neutrophils is regulated 
by IFN-. Tumors and blood were harvested at day 14 after tumor inoculation, single cell 
solutions prepared, stained and CD11b+Gr1+ neutrophils were sorted out. RNA was isolated, 
cDNA prepared and gene expression of Bax (A) and BCL-xL (B) measured using quantitative RT-
PCR. To visualize a pro- or anti-apoptotic expression pattern of these two Bcl-2 family members 
the Bax/BCL-xL ratio was assessed (C). Cells were derived from five pooled animals. All 
experiments were repeated at least one time. 
4.2.6. Altered expression of major apoptosis regulators and apoptosome components in 
the absence of endogenous IFN-β 
As a consequence of Bax dependent mitochondrial outer membrane permeabilization, 
cytochrome c is released and apoptosome formation is induced. Apaf1 oligomerizes and the 
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apoptosome accomplishes cleavage and activation of pro-caspase 9, an initiator caspase that 
induces processing of downstream caspases (Li et al., 1997; Slee, 1999). To investigate the 
role of apoptosome components in IFN- dependent apoptosis of neutrophils derived from 
blood (Fig.4.14. A and B) or tumor (Fig.4.14. C and D), C57BL/6 and Ifnb1
-/-
 mice were 
challenged s.c. with B16F10 melanoma cells. On day 14 after tumor inoculation, neutrophils 
were isolated from the different tissues and qRT-PCR analysis were performed. 
 
Figure 4.14. Altered expression of major regulators of apoptosis and apoptosome 
constituents in the absence of endogenous IFN-β. To evaluate expression level of Apaf1, 
caspase 8 and cFLIP, mice were s.c. injected with B16F10 tumor cells. On day 14 after tumor 
inoculation Ly6G+ CD11b+ neutrophils from (A) blood and (C) tumor of wild type or syngeneic 
Ifnb1-/- mice were sorted using a BD FACS Aria system, mRNA was isolated and quantitative RT-
PCR analyses performed. Data represent pools of at least 6 mice per group. In addition, the 
caspase 9 activity was assessed in Ly6G+ CD11b+ neutrophils from (B) blood and (D) tumor by 
FACS analysis, using FITC coupled caspase inhibitor FAM-FLICA. The experiment was repeated 
twice with at least 5 mice per group and statistical significance was determined using unpaired 
students t test or one way ANOVA with turkey posttest (*p≤0,05). 
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Apparently, Apaf-1 and caspase 8 expression was downregulated in the absence of 
endogenous IFN- in neutrophils from blood (Fig.4.14 A) and tumor (Fig.4.14 B). Besides, 
also the FADD-like interleukin-1-converting enzyme (FLICE)-inhibitory protein (cFLIP), a 
major anti-apoptotic regulator (Safa, 2012), could be involved in the altered apoptosis rate of 
Ifnb1
-/-
 neutrophils. Interestingly, cFLIP expression was significantly higher in blood derived 
neutrophils from wild type mice (Fig.4.14 A), but no differences were observed in TAN 
(Fig.4.14 B).  
Additional analysis of neutrophils for cytochrome c release (Fig.4.14) and caspase 9 activity 
(Fig.4.14 B and D) revealed no significant changes regarding blood neutrophils from IFN- 
sufficient or deficient tumor-bearing mice (Fig.4.14 B; Fig.4.14 A and B). In contrast, tumor 
derived neutrophils of Ifnb1
-/-
 mice displayed reduced caspase 9 activity (Fig.4.14 D) 
compared to wild type controls, although no differences in cytochrome c release could be 
detected (Fig.4.15 C and D). 
 
Figure 4.15. Cytochrome c release of neutrophils is not influenced by endogenous IFN-. 
To assess the cytochrome c release of mitochondria in neutrophil granulocytes, B16F10 
melanoma cells were injected s.c. on the back of C57BL/6 and syngeneic Ifnb1-/- mice. On day 14 
after tumor inoculation single cell suspensions of blood (A and B) and tumor (C and D) were 
prepared and stained for Ly6G, CD11b and cytochrome c. No significant differences were 
detected. 
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4.2.7. Reduced pro-apoptotic signaling in neutrophils of tumor bearing Ifnb1-/- 
mice decreases effector caspase activity 
Caspases are crucial for the initiation, propagation, and execution of apoptosis. Neutrophils 
express a set of six pro-apoptotic caspases, three initiator caspases (8, 9, and 10) and three 
effector caspases (3, 6 and 7) (Chang and Yang, 2000). They are activated via two main 
pathways: the extrinsic death receptor pathway and the intrinsic mitochondrial pathway 
induced by DNA damage or oxidative stress (Galluzzi et al., 2012b; Degterev and Yuan, 
2008). Upon activation, pro-caspases are cleaved leading to the formation of mature caspases 
(Chang and Yang, 2000). Since important pro-apoptotic stimuli, as well as initiator caspase 
expression (Fig.4.14 A and C) and activity (Fig.4.14 B and D) were altered in neutrophils of 
tumor bearing Ifnb1
-/-
 mice, it was analyzed whether the expression or activation level of the 
effector caspase 3 is also affected.  
Therefore, neutrophils from blood, tumor and lung of mice bearing B16F10 melanoma were 
tested for the expression of caspase 3 using qRT-PCR. A strong reduction of caspase 3 
expression was detected in neutrophils of tumor bearing Ifnb1
-/-
 mice, compared to control 
animals. This was true for all three anatomical compartments (Fig.4.16 A), although 
expression levels were dramatically lower in neutrophils from blood and lung, compared to 
tumors.  
To address the post-transcriptional regulation of caspase 3, the status of the active form of 
this protease was assessed. As expected, tumors of wild type animals displayed the highest 
percentage of neutrophils containing active caspase 3 (Fig.4.16 B and C), that was 
significantly reduced in the absence of endogenous IFN-. Regarding blood and lung of 
tumor bearing animals a lower percentage of neutrophils appeared positive for active caspase 
3, compared to tumor tissue (Fig.4.16 B and C). Nevertheless, the absence of endogenous 
IFN- further reduced it. Thus, consistent with the enhanced longevity of neutrophils in 
tumor bearing Ifnb1
-/-
 mice, expression of mature effector caspase 3 was reduced in 
neutrophils from various anatomical compartments on C57BL/6 as well as BALB/c 
background (Fig.4.16, Fig.4.17). 
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Figure 4.16. Neutrophils of Ifnb1-/- tumor bearing mice show a decreased caspase 3 
activity. To assess the relative gene expression of caspase 3 (A), quantitative RT-PCR for blood, 
tumor and lung was performed. To measure the activity of the effector caspase 3 (B and C) in 
blood, tumor and lung neutrophils, B16F10 melanoma cells were s.c. injected to the back of 
C57BL/6 or Ifnb1-/- mice. On day 14 after tumor inoculation single cell suspensions of the 
different organs were prepared and analyzed using the LSR II system. The experiment was 
repeated two times and statistic significance was evaluated using unpaired students t test (* p≤ 
0,05). 
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Figure 4.17. Neutrophils of Ifnb1-/- tumor bearing mice show a decreased caspase 3 
activity independent of mouse strain or tumor model. To measure the activity of the 
effector caspase 3 in blood (A), tumor (B) and lung (C) neutrophils, 4T1 cells were s.c. injected 
to the mammary fat pad of BALB/c or Ifnb1-/- mice. On day 14 after tumor inoculation single cell 
suspensions of the different organs were prepared and analyzed using the LSR II system. The 
experiment was repeated two times and statistic significance was evaluated using unpaired 
students t test (* p≤ 0,05). 
4.2.8. G-CSF expression is increased in the absence of endogenous IFN- 
Neutrophil life span and survival are also regulated by growth factors like Granulocyte 
Colony Stimulating Factor (G-CSF). To further investigate the mechanisms underlying the 
prolonged life span of neutrophils in tumor bearing Ifnb1
-/-
 mice, the serum levels of G-CSF 
was analyzed by ELISA in presence and absence of endogenous IFN-. Additionally, G-CSF 
expression in neutrophils was assessed by qRT-PCR.  
Interestingly, the relative expression of G-CSF in neutrophils derived from blood, tumor and 
lung of tumor bearing Ifnb1
-/-
 mice was remarkably increased, in comparison to wild type 
animals, but apparently not influenced in spleen (Fig. 4.18). Expression levels were strongly 
reduced when Ifnb1
-/-
 neutrophils were incubated with low amounts of rmIFN- (Fig.4.18 A). 
Congruent results were obtained for serum G-CSF. On day 14 after tumor injection, Ifnb1
-/-
 
mice showed a significantly increased concentration of G-CSF in serum (Fig. 4.18 E). 
The G-CSF receptor signals via the PI3K/Akt pathway to inhibit the pro-apoptotic Bcl-2 
family member Bax. To test whether the enhanced serum G-CSF level observed in the 
absence of endogenous IFN- has an impact on G-CSF signaling in tumor tissue, the 
phosphorylation status of PI3 kinase was analyzed. A drastic increase of pPI3K was detected 
in IFN- deficient mice, compared to controls (Fig.4.18 F). Taken together, this indicates an 
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impact of IFN-on the regulation of G-CSF expression underlining the important role of 
type I IFN in the context of neutrophil life cycle. 
 
Figure 4.18. Increased G-CSF expression in the absence of endogenous IFN-β. To evaluate 
serum G-CSF level, mice were s.c. injected with B16F10 tumor cells. On day 14 after tumor 
inoculation heart blood was harvested to perform serum ELISA (E). In addition Ly6G+ CD11b+ 
neutrophils from (A) blood, (B) tumor, (C) lung and (D) spleen of tumor bearing wild type or 
syngeneic Ifnb1-/- mice were sorted using a BD FACS Aria system, mRNA was isolated and 
quantitative RT-PCR analyses performed. The important regulatory function of IFN-β was 
verified by 4 hours incubation of blood neutrophils in the presence or absence of recombinant 
IFN-β and subsequent qRT-PCR. 2 independent experiments were performed, with at least 5 
mice per group. Statistical significance was determined using unpaired Students t-test (** p ≤ 
0,005). In addition the phosphorylation status of the G-CSF signal transducer PI3 kinase (F) was 
analyzed by western blot for tumor tissue of C57BL/6 mice and syngeneic Ifnb1-/- mice. 
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4.3. Impact of endogenous IFN- on the phenotypic polarization of TAN 
The concept of dichotomous activation and polarization is well established for tumor 
associated macrophages that were shown to exhibit both anti-tumor (M1) as well as pro-
tumor (M2) functions, depending on the respective micromilieu (Sica and Mantovani, 2012). 
In 2009 a comparable concept was suggested for TAN by Fridlender and colleagues who 
identified TGF- as one of the factors responsible for the induction of an N2 pro-tumor 
neutrophil phenotype (Fridlender et al., 2009). Indeed, these pro-tumorigenic neutrophils 
seem to be distinct from granulocytic MDSCs or naive neutrophils (Fridlender et al., 2012) 
and accumulate during tumor progression (Mishalian et al., 2013). Increasing evidence 
suggests that IFN- could play a role in N1 anti-tumor polarization of TAN. It massively 
influences tumor growth as well as angiogenesis in a neutrophil dependent manner 
(Jablonska et al., 2010). In addition, it regulates neutrophil chemotaxis (Jablonska et al., 
2013) and influences neutrophil maturation, turn over and apoptosis. Therefore, the present 
work was directed to further investigate the impact of type I IFNs on TAN polarization. To 
this end, different characteristics of neutrophils known to be associated with either N1 anti-
tumor or N2 pro-tumor function were assessed in presence or absence of endogenous IFN-  
4.3.1. Altered expression of co-stimulatory molecules and activation markers on 
Ifnb1-/- TAN 
One functional ability of neutrophils is the induction of an adaptive immune response, 
including the activation of DCs and effector T cells (Fridlender and Albelda, 2012). To this 
end, neutrophils are able to express different co-stimulatory molecules such as CD80, CD86 
or ICAM1 (Mantovani et al., 2011). Interestingly, especially the latter one seems to be down 
regulated on N2 pro-tumor neutrophils (Piccard et al., 2012). To further elucidate the 
influence of endogenous IFN- on the phenotype of TANs, flow cytometric analysis of 
ICAM1 expression were performed on day 14 after s.c. inoculation of B16F10 melanoma or 
4T1 mammary carcinoma in wild type or Ifnb1
-/-
 animals (Fig.4.19). 
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Figure 4.19. ICAM1 expression is downregulated on tissue neutrophils in the absence of 
endogenous IFN-. To assess the expression of the co-stimulatory adhesion molecule ICAM1 
on neutrophils from different sources, C57BL/6 and BALB/c mice, as well as syngeneic Ifnb1-/- 
animals, were challenged with B16F10 or 4T1 tumors, respectively. On day 14 after tumor 
inoculation, single cell suspension of blood (A, B), tumor (C, D) and lung (E, F) were prepared 
and analyzed for ICAM1 expression on CD11b+ GR1+ neutrophilic granulocytes via flow 
cytometry. The experiment was repeated twice with at least five mice per group and statistical 
significance was calculated using unpaired students t test (*p≤0,05). 
No significant changes were observed for blood neutrophils in presence or absence of 
endogenous IFN- (Fig.4.19. A and B). Of note, the expression of ICAM1 was remarkably 
upregulated after neutrophil transmigration into the target tissue (Fig.4.19. C to F). This 
upregulation was significantly reduced in the absence of endogenous IFN- in tumor 
(Fig.4.19. C and D) as well as in lung (Fig.4.19. E and F) independent of the mouse strain. 
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This further validates an influence of type I IFNs on the activation and polarization of 
neutrophilic granulocytes. 
4.3.2. Altered neutrophil activation in tumor bearing Ifnb1-/- mice 
Besides ICAM1 upregulation (Fortunati et al., 2009), also the shedding of L-selectin CD62L 
is associated with the neutrophil maturation and activation status (Pillay et al., 2012a). 
Therefore, CD62L expression on blood and tumor neutrophils was assessed by flow 
cytometry to further characterize the neutrophilic phenotype (Fig.4.20.).   
 
Figure 4.20. Accumulation of CD62Lhi neutrophils in the blood of Ifnb1-/- mice. To assess 
the expression of L-selectin on neutrophils, C57BL/6 and BALB/c mice, as well as syngeneic 
Ifnb1-/- animals, were challenged with B16F10 or 4T1 tumors, respectively. On day 14 after 
tumor inoculation single cell suspension of blood (A, B) and tumor (C, D) were prepared and 
analyzed for CD62L expression on CD11b+ GR1+ neutrophilic granulocytes via flow cytometry. 
The experiment was repeated twice with at least five mice per group and statistical significance 
was calculated using unpaired students t test (*p≤0,05). 
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Consistent with the observed accumulation of immature neutrophils in circulation of tumor 
bearing Ifnb1
-/-
 animals (Fig. 4.8.), a significantly increased percentage of CD62L
+
 
neutrophils was detected in the blood of tumor bearing BALB/c mice deficient for 
endogenous IFN- (Fig.4.20 C). The same effect was observed for C57BL/6 mice, but the 
difference was statistically not significant (Fig.4.20. A). Interestingly, once extravasated into 
the tumor tissue, CD62L expression did apparently not depend on presence or absence of 
endogenous IFN-any more (Fig.4.20. B and D). 
4.3.3. TAN do not secret arginase 1 or suppress T cell proliferation 
In contrast to the immunostimulatory functions of anti-tumor N1 neutrophils, pro-tumor N2 
neutrophils were reported to exert immunosuppressive function towards T cells (Mayadas et 
al., 2014). Such TANs were shown to produce arginase 1 (Fridlender and Albelda, 2012) or 
inhibit T cell responses by the secretion of ROS in a cell contact dependent manner via Mac-
1 (Pillay et al., 2012b). To test whether the ability of neutrophils to produce arginase 1 is 
influenced by endogenous IFN- C57BL/6 and syngeneic Ifnb1-/- mice were challenged with 
B16F10 melanoma. On day 14 after tumor inoculation arginase 1 content in blood (Fig.4.21. 
A) or tumor (Fig.4.21. B) derived neutrophils was assessed via flow cytometry. 
 
Figure 4.21. Arginase 1 production of neutrophils from blood and tumor in presence or 
absence of endogenous IFN-. To assess the arginase 1 content of neutrophils from different 
sources, C57BL/6 and syngeneic Ifnb1-/- animals were challenged with B16F10 melanomas. On 
day 14 after tumor inoculation single cell suspension of blood (A,) and tumor (B) were prepared 
and analyzed for arginase 1 expression of CD11b+ GR1+ neutrophilic granulocytes via flow 
cytometry. The experiment was repeated twice with at least five mice per group. 
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Apparently, no significant differences in neutrophils from the different anatomical 
compartments were observed in presence and absence of endogenous IFN-. The mean 
fluorescence intensity detected for neutrophilic arginase 1 was generally very low and close 
to the detection limit. 
 
Figure 4.22. Neutrophils from tumor bearing mice show no T cell suppressive capacity. 
To assess suppressive activities of neutrophils CD4+CD25- CD3 stimulated responder T cells 
from BALB/c mice were co-cultivated in different ratios with CD4+CD25+ regulator T cells 
derived from BALB/c mice or sorted neutrophils from blood (A) or tumors (B) of wild type or 
Ifnb1-/- animals. T cell proliferation rate was assessed after 72h by 3H-thymidine incorporation. 
The experiment was repeated 3 times. 
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In line with this, neutrophils sorted from blood (Fig.4.22. A) or tumor (Fig.4.22. B) of wild 
type and syngeneic Ifnb1
-/-
 mice failed to suppress CD3 mediated T cell proliferation. 
Instead, neutrophil co-culture stimulated T cell proliferation and neither anatomical 
compartment nor genotype of the respective granulocytes abrogated this effect. 
4.3.4. Reduced killing capacity of neutrophils in Ifnb1-/- mice
Neutrophils, besides their immunoregulatory functions, have the capacity to directly kill 
tumor cells (Hicks et al., 2006). This ability is remarkably reduced in N2 TANs (Fridlender 
and Albelda, 2012) and it is unclear which factors influence this process. Therefore, 
neutrophil cytotoxicity against tumor cells was tested in tumor bearing mice deficient or 
sufficient for IFN-. To this end, neutrophils derived from blood and tumor of BALB/c 
(Fig.4.23. A), C57BL/6 (Fig.4.23. B) or syngeneic Ifnb1
-/-
 animals were sorted and co-
cultivated with luciferase expressing 4T1 tumor cells at an effector-target ratio of 2:1 for 18 
hours with or without the addition of rmIFN-. The luciferase activity of living tumor cells 
was subsequently measured using the IVIS 200 in vivo imaging system. 
Indeed, cytotoxicity against tumor cell was significantly reduced in neutrophils sorted from 
blood (Fig.4.23. A) and tumor (Fig.4.23. A and B) of Ifnb1
-/-
 animals. However, addition of 
low amounts of rmIFN- to the culture medium completely restored the killing capacity of 
Ifnb1
-/-
 neutrophils. Interestingly, a general reduction of neutrophilic killing ability was 
detected for TANs in comparison to blood derived neutrophils, indicating further influences 
of the tumor microenvironment on neutrophilic functions. 
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Figure 4.23. Reduced killing capacity of neutrophil granulocytes in the absence of 
endogenous IFN-. To evaluate the ability of neutrophils from tumor bearing mice to kill tumor 
cells, BALB/c (A) and C57BL/6 (B) mice as well as syngeneic Ifnb1-/- animals were challenged 
with 4T1 or B16F10 tumors, respectively. On day 14 after tumor inoculation neutrophils from 
blood and tumors were sorted and co-incubated with luciferase expressing 4T1 tumor cells in 
an effector target ration of 2 to 1 for 18 h. Afterwards the luciferase activity of the residual 
living tumor cells was measured using an IVIS in vivo imaging system. The experiment was 
repeated twice, with at least five mice per group and statistical significance was calculated using 
unpaired students t test (*p≤0,05). 
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4.3.5. Ifnb1-/- tissue neutrophils produce decreased amounts of TNF-
In 1975 Carswell, Old and colleagues identified an endo-toxin induced serum factor that 
induces tumor necrosis and named it TNF-(Carswell et al., 1975). Nowadays, this cytokine 
is known as a major regulator of inflammation that can exert both, pro-tumor as well as anti-
tumor functions, depending on its concentration (Balkwill, 2009). Importantly, the tumor 
toxic effect of TNF- is not only due to direct cytotoxic or cytostatic effects on the tumor 
cells, but can also be attributed to its immunostimulatory and vessel disrupting functions 
(Daniel and Wilson, 2008). Of note, one important feature of N1 anti-tumor neutrophils is the 
local production of TNF- at tumor site (Fridlender and Albelda, 2012).  
Therefore, to further elucidate the impact of endogenous IFN- on TAN polarization, 
neutrophilic TNF- production was assessed in different anatomical compartments of tumor 
bearing C57BL/6 as well as BALB/c mice and syngeneic Ifnb1
-/-
 animals (Fig.4.24). 
In both tumor models applied, no differences regarding the percentage of TNF- producing 
blood neutrophils were detected (Fig.4.24. A and B). However, neutrophilic TNF- 
production was remarkably increased after transmigration into target tissue. Most probably 
due to the activation of such cells (Fig.4.24. C to E). This migration associated polarization 
appeared to be strongly influenced by endogenous IFN-. Neutrophils from tumor (Fig.4.24. 
C) as well as lung (Fig.24.4. E and F) displayed a significantly reduced expression of TNF- 
in comparison to wild type controls. This was true for all mouse strains or tumor models 
tested. 
 
Results 
72 
 
 
Figure 4.24 Decreased TNF- production by neutrophils from tumor bearing Ifnb1-/- mice. 
To assess the production of TNF- by neutrophils, C57BL/6 and BALB/c mice, as well as 
syngeneic Ifnb1-/- animals, were challenged with B16F10 or 4T1 tumors, respectively. On day 14 
after tumor inoculation single cell suspension of blood (A, B), tumor (C, D) and lung (E, F) were 
prepared and analyzed for TNF- expression in CD11b+ GR1+ neutrophilic granulocytes via flow 
cytometry. The experiment was repeated twice with at least five mice per group and statistical 
significance was calculated using unpaired students t test (*p≤0,05). 
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4.4. Influences of type I IFN tumor therapy on neutrophil polarization 
Just shortly after the discovery of type I IFNs by Isaacs and Lindenmann (Isaacs and 
Lindenmann, 1987) the investigation of their therapeutic potential started. Nowadays, type I 
IFNs, i.e. IFN- and IFN-, are in clinical use for treatments of a broad variety of diseases, 
such as multiple sclerosis (Verweij and Vosslamber, 2013) or hepatitis C virus infections 
(Pawlotsky, 2013, 2014). In cancer therapy type I IFNs are also successfully applied for 
different tumor entities, including renal cell carcinoma or hairy cell leukemia (Wang et al., 
2011) even though the exact mechanism of action is not clear to date. Besides direct 
cytostatic and cytotoxic effects of type I IFN on the tumor cells, several immunomodulatory 
effects are attributed to such treatments (Gajewski et al., 2012). Nevertheless, neutrophil 
polarization under type I IFN therapy has not been investigated thus far and therefore it 
became one of the aims of this thesis. Indeed, an effect of endogenous IFN- on the 
polarization of tumor associated neutrophil granulocytes was elucidated. To additionally 
specify the effect of therapeutic IFN- on neutrophil polarization, such cell isolated from 
tumor-bearing mice undergoing IFN- treatment were phenotypically characterized. 
4.4.1. Therapeutic intervention with type I IFNs induces an N1 anti-tumor 
neutrophil phenotype 
High dose type I IFN therapy, as it is currently used in the clinics to treat different diseases, is 
often accompanied by severe side effects. This could negatively influence patient compliance 
and not seldom leads to the discontinuation of treatment (Kiladjian et al., 2011; Mocellin et 
al., 2013). Thus, it was of special interest to determine the effects of low dose type I IFN 
therapy on disease modifying aspects like immunosurveillance. Therefore, C57BL/6 as well 
as BALB/c mice and syngeneic Ifnb1
-/-
 animals were challenged with B16F10 melanomas or 
4T1 mammary carcinomas and treated i.v. with low doses of rmIFN- On day 14 after tumor 
inoculation neutrophilic phenotype was assessed by flow cytometry (Fig.4.25 and Fig.4.26.). 
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Figure 4.25. Phenotypic characterization of TAN upon low dose IFN- therapy. C57BL/6 
(A,C,E,G), BALB/c (B, D, F, H) wild type mice and syngeneic Ifnb1-/- animals were s.c. injected 
with B16F10 or 4T1 tumor cells, respectively. From day 3 after tumor inoculation onwards low 
dose IFN- therapy was i.v. applied every other day. On day 14 after tumor inoculation single 
cell suspensions from tumor tissue were analyzed for the expression pattern of N1/N2 markers 
ICAM1, Fas, TNF- and active caspase 3. The experiment was repeated at least once with five 
mice per group and statistical significance was calculated using unpaired students t test 
(*p≤0,05). 
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Type I IFN therapy induced neutrophil polarization towards an N1 like phenotype. On 
C57BL/6 background this was especially significant for the co-stimulatory cell-adhesion 
molecule ICAM1 (Fig.4.25. A). Also the other polarization marker tested showed a tendency 
of upregulation. This might indicate an N1 polarization as therapeutic effect of the IFN- 
application (Fig.4.25. C, E and G). Especially the treatment of BALB/c mice resulted in the 
upregulation of the N1 marker TNF- (Fig.4.25. F). Additionally, caspase 3 (Fig.4.25. H) 
was significantly upregulated upon type I IFN treatment. Moreover the extracellular N1 
marker Fas (Fig.4.25. D) as well as ICAM1 (Fig.4.25. B) showed a slightly increased 
expression in response to the treatment. 
4.4.2. Therapeutic polarization of neutrophils in the pre-metastatic lung 
Metastasis is the spread of tumor cells from the primary lesion to another, non-adjacent 
organ. Importantly, multi organ failure due to metastasis causes 90% of the cancer associated 
deaths (Gupta and Massagué, 2006). Even though it would be highly desirable to directly 
target and control metastatic processes, the molecular mechanisms underlying this fatal 
devolution are largely elusive to date. Besides different tumor and target organ features that 
are known to determine the preferential metastatic sites, also the so called pre-metastatic 
niche is involved in the establishment of metastasis (Sceneay et al., 2013). Especially for 
lung metastasis, involvement of neutrophilic granulocytes in the formation of a permissive 
pre-metastatic niche has been demonstrated (Kowanetz et al., 2010). Type I IFNs seem to be 
involved in the regulation of this process (W & Andzinski et al. submitted). Therefore, the 
impact of a therapeutic intervention on lung neutrophil polarization using type I IFNs was 
characterized in the present work. C57BL/6 and BALB/c mice were challenged with B16F10 
melanoma or 4T1 mammary carcinoma cells that are known to spontaneously metastasize to 
the lung (Parhar and Lala, 1987; Smith et al., 2004). Tumor bearing mice were treated with 
low amounts of rmIFN- for a period of 14 days. Subsequently phenotypic polarization of 
lung neutrophils was analyzed using flow cytometry (Fig.4.26.). 
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Figure 4.26. Phenotypic characterization of neutrophils in the pre-metastatic lung upon 
low dose IFN- therapy. C57BL/6 (A,C,E,G) and BALB/c (B, D, F, H) wild type mice, as well as 
syngeneic Ifnb1-/- animals, were s.c. injected with B16F10 or 4T1 tumor cells, respectively. From 
day 3 after tumor inoculation low dose i.v. IFN- therapy was applied every other day. On day 
14 after tumor inoculation single cell suspensions from lung tissue were analyzed for the 
expression pattern of N1/N2 markers ICAM1, Fas, TNF- and active caspase 3. The experiment 
was repeated at least once with five mice per group and statistical significance was calculated 
using unpaired students t test (*p≤0,05). 
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Regarding both tumor models, low dose IFN- therapy clearly induced an N1 polarization of 
neutrophils in the pre-metastatic lung (Fig.4.26.). This was especially significant for the 
production of TNF- (Fig.4.26. E and F) and the activity of effector caspase 3 (Fig.4.26. G 
and F) that were drastically upregulated upon treatment. Referring to the regulation of the N1 
associated marker ICAM1 (Fig.4.26. A and B) and Fas (Fig.4.26. C and D) enhanced 
expression after therapeutic intervention was also detectable, indicating an influence of 
exogenous type I IFN therapy on neutrophil polarization in the pre-metastatic niche.  
Taken together, these data demonstrate the high significance of therapeutic as well as 
endogenous IFN- on the polarization of N1 anti-tumor TANs. In a long run this might 
influence the development of new therapeutic approaches targeting endogenous type I IFN 
induction to facilitate efficient immunosurveillance of cancer.  
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5. Discussion 
The importance of neutrophils in the biology of cancer is well established now. Even though 
there are controversies regarding the differences between granulocytic myeloid-derived 
suppressor cells and TANs (Dumitru et al., 2012; Brandau et al., 2013). Especially their 
contribution to tumor angiogenesis, immunosurveillance and invasive growth became 
increasingly clear over the years (Jablonska et al., 2010; Fridlender et al., 2009; Gabrilovich 
et al., 2012b). Moreover, neutrophils represent an important prognostic marker in a broad 
variety of neoplasias. For instance, a high number of intra-tumoral neutrophils in localized, as 
well as metastatic renal cell carcinoma, correlates with a negative prognosis (Jensen et al., 
2009). Similarly, infiltration by neutrophils has been correlated in gliomas with higher tumor 
stages (Fossati et al., 1999) and in pancreas carcinomas with more aggressive tumor 
phenotypes (Reid et al., 2011). In accordance, tumor infiltrating neutrophils represent a 
highly potent therapeutic target. Thus, understanding the physiology of tumor infiltrating 
neutrophils is of utmost importance. 
The role of type I IFNs in this context was recently demonstrated. Higher numbers of 
neutrophils accumulate in tumors of mice that lack endogenous IFN- Such neutrophils not 
only produce higher amounts of pro-angiogenic factors, compared to their WT counterparts, 
but also secrete increased amounts of neutrophil attracting chemokines (Jablonska et al., 
2010, 2013). The present work now adds further evidence for the major role of type I IFNs in 
the regulation of cancer immunosurveillance via the polarization of neutrophilic granulocytes 
and demonstrates for the first time a Sting dependent induction of IFN- production by tumor 
infiltrating DCs. 
5.1. IFN- induction in solid tumors 
The importance of endogenous type I IFNs in immunosurveillance of cancer is widely 
accepted and different approaches to abrogate type I IFN responses, like using neutralizing 
antibodies or knockout mice (IFNAR
-/-
, Ifnb1
-/-
), revealed significantly faster tumor growth 
and invasiveness of a broad variety of murine tumor models upon type I IFN deficiency 
(Gresser et al. 1990; Picaud et al. 2002; Gresser & Belardelli 2002; Jablonska et al. 2010). 
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This influence of type I IFN can be attributed to both, direct as well as indirect effects on the 
tumor cells. Hence, type I IFNs were demonstrated to increase the expression levels of MHC 
I (Maguire et al. 1990), enhance tumor antigen expression on the cell surface (Lindahl et al. 
1973) or induce growth arrest and apoptosis in cancer cells (Bekisz et al. 2013; Takaoka et al. 
2003).  
In addition, endogenous type I IFNs exert diverse immunomodulatory functions. They are 
involved in cancer immunoediting (Dunn et al. 2005; Dunn et al. 2006), and activate innate 
immune cells e.g. NK cells (Gresser et al. 1994; Gill et al. 2011) or macrophages (Bekisz et 
al. 2013). Moreover, type I IFNs promote the adaptive anti-tumor response by suppressing 
regulatory T cells (Fradelizi & Gresser 1982), activating cytotoxic CD8
+
 T cells (Harlin et al. 
2009) as well as DCs (Bald et al. 2014) and enhancing humoral immunity (Le Bon et al. 
2001). Despite these tremendous beneficial effects and the number of mechanisms described 
to date, some key aspects of type I IFN action during tumor progression are still unknown. Is 
constitutively produced type I IFN regulating all these phenomenons or is the IFN induced in 
growing tumors? If induced, which signaling pathways are involved and which cells 
contribute to the induced or constitutive IFN production?  
The present work demonstrates type I IFN induction in different murine tumor models by 
using a very sensitive reporter mouse approach (Lienenklaus et al. 2009). However, other 
studies failed to detect induction of IFN- in different spontaneous or transplantable tumor 
models (Gresser & Belardelli 2002). This controversy is likely due to the lower sensitivity of 
the methods used in the opposing papers. The luciferase reporter system in contrast can easily 
localize sites of IFN induction in a Listeria monocytogenes infection model where IFN- is 
hardly detectable by ELISA (Solodova et al. 2011). Indeed, the IFN- signal detected at 
tumor sites was relatively low, though clearly elevated above background IFN- expression. 
It reached levels, typically detected in the thymus, the organ with the highest constitutive 
IFN- expression (Lienenklaus et al. 2009).  
Regarding the cellular source of type I IFNs at tumor site, the present results indicate that 
both, invading host cells as well as tumor cells, express IFN- in vivo. Interestingly, no IFN-
 was produced by tumor cells in cell culture. Thus, the tumor micromilieu in vivo apparently 
induces a type I IFN response in tumor cells. The signals however are still unclear and the 
importance of this tumor derived type I IFN in clinical settings remains to be determined. Of 
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note, in different human tumors such as glioblastoma multiforme (Sgorbissa et al. 2011) or 
malignant melanoma (Culig 2013; Lenci et al. 2012) mutations targeting the type I IFN 
system have been observed. Thus, it appears that during tumor development a counter 
selection against a functional type I IFN response takes place. To this end, the mechanisms 
and relevance of tumor cell derived type I IFN should be further investigated under 
physiological conditions in cancer patients. 
Nevertheless, host cell derived type I IFN is of utmost importance in cancer surveillance 
(Gresser & Belardelli 2002). Here, by applying a tissue specific reporter mouse model 
(Solodova et al. 2011), the IFN- producing cell population at tumor site could be revealed. It 
is characterized as Tie2
+
 LysM
+
 CD11c
+
 CD19
-
 and partly CD4
+
. This indicates cells, that 
derive from hematopoietic precursors (Tie2) (Constien et al. 2001) and belong to the myeloid 
lineage (Hume 2011). Moreover, the cell population of interest expresses CD11c and a part 
expressed CD4 at least once in their life time. These observations suggest a population of 
infiltrating myeloid DCs (Shen et al. 2014; Haniffa et al. 2013) as cellular source of tumor-
induced type I IFNs. Indeed, sorting of CD11b
+
 CD11c
+
 mDCs from tumor tissue in 
combination with subsequent qRT-PCR analysis revealed substantial IFN- expression in 
such cells in comparison to splenic mDCs or B cells. This is in line with the observation, that 
IFN induction in the tumor is partially dependent on IRF3 and IRF5 as it has been previously 
described for IFN- induction in DCs (Lazear et al. 2013). 
In general, three major receptor systems can be involved in mounting a type I IFN response, 
namely TLRs, RLRs and CDRs (Gonzalez-Navajas et al. 2012). Crossing the IFN- reporter 
mouse with knockout mutants for the respective adaptor proteins of these PRRs allowed to 
demonstrate that neither TLR nor RLR receptor signaling is responsible for tumor-induced 
type I IFN expression. The absence of the CDR signaling adaptor protein Sting (Keating et 
al. 2011; Paludan & Bowie 2013) however, substantially reduced IFN- gene expression in 
tumor tissue. Therefore, it can be speculated that DNA of dying tumor cells might be the 
ligand inducing type I IFN expression in tumor tissue. Actually, it is known that cell death, 
for example induced by chemotherapeutic agents, can lead to the release of DAMPS that 
subsequently activate the immune system (Green et al. 2009). Furthermore, the anti-microbial 
peptide LL37, which is over expressed in psoriasis patients, very efficiently transports 
extracellular self-DNA into plasmacytoid DCs (Lande et al. 2007) or monocytes (Chamilos et 
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al. 2012) thus facilitating TLR or Sting mediated type I IFN induction, respectively. 
Moreover, TLR independent type I IFN induction has been reported upon phagocytosis of 
apoptotic cells by DNase II-deficient macrophages. Hence, the massive cell death in tumors 
accompanied by environmental conditions provoking defective DNA degradation in APCs is 
a potential mechanism mediating type I IFN induction in tumor infiltrating mDCs (Fuertes et 
al. 2013).  
Sting was recently demonstrated to be involved in type I IFN induction upon DNA 
recognition. However, it is apparently not a direct DNA sensor (Keating et al. 2011). Further 
research is needed, to identify the receptor responsible for Sting mediated type I IFN 
expression. A possible candidate might be interferon inducible protein 16 (IFI16) which has 
been demonstrated to recruit Sting and initiate a TBK1-IRF3-dependant IFN- induction in 
response to self and non-self DNA ligands (Unterholzner et al. 2010; Keating et al. 2011; 
Paludan & Bowie 2013). Interestingly, IFI16 is also known as tumor-suppressor exhibiting 
pro-apoptotic, anti-angiogenic as well as immunostimulatory effects (Mazibrada et al. 2010). 
Variation in constitutive IFI16 expression might be associated with human diseases 
(Choubey et al. 2008). 
Recently, a loss-of-function variant of Sting was identified in humans (Jin et al. 2011). The 
resulting protein displays ≥90% decrease regarding its ability to stimulate IFN- production 
in response to Listeria monocytogenes infection clearly emphasizing the relevance of Sting in 
humans. Importantly, the authors assume that approximately 3% of the American population 
is homozygous for this mutation. It would be very interesting to further investigate the impact 
of this genetic variant on tumor development especially in the light of the present study. 
Unfortunately no data on cancer associated deaths are available for this cohort so far.  
Taken together the present findings regarding tumor-induced, Sting-IRF3/IRF5-mediated 
type I IFN expression in tumor infiltrating mDCs have important implications. They reveal 
potent targets for future cancer therapy and significantly improve our understanding of the 
molecular mechanisms underlying type I IFN modulated immunosurveillance of tumors. 
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5.2. IFN- regulates the life span and polarization of neutrophils under tumor 
conditions 
In WT tumor bearing mice, the live span of neutrophils is significantly shorter compared to 
neutrophils from IFN- deficient animals. This is partially due to the fact that IFN- is able 
to influence both the extrinsic as well as the intrinsic apoptosis pathways of neutrophilic 
granulocytes.  
ROS production by neutrophils might play an important role in this context. For instance, a 
delayed rate of spontaneous neutrophil apoptosis was demonstrated in patients deficient for 
the enzyme NADPH oxidase (Kuijpers and Lutter, 2012; Kasahara et al., 1997). In line with 
this, it has been shown that hypoxia as well as pharmacological inhibition of NADPH 
oxidase and hydrogen peroxide scavengers are capable to decrease the rate of spontaneous 
neutrophil apoptosis (Lundqvist-Gustafsson and Bengtsson, 1999). The present data indicate 
that spontaneous production of ROS is diminished in the absence of endogenous IFN-β, thus 
potentially contributing to the delayed apoptosis of tumor infiltrating neutrophils in Ifnb1
-/-
 
mice and their accumulation in the neoplasia. The regulatory mechanism by which this 
cytokine influences the production of small molecules like ROS remains to be determined. 
Nevertheless, an influence of type I IFNs on ROS induced apoptosis has been demonstrated 
in hematopoietic cells deficient for the ISG UBP-43 (Yim et al., 2012). These cells are 
hypersensitive towards IFN-induced apoptosis and upregulate their ROS production after IFN 
treatment. Furthermore, the reduction of ROS by the treatment with ROS scavengers 
simultaneously reduced the type I IFN-mediated apoptosis in such cells (Yim et al., 2012). 
The present results confirm these findings. Lower numbers of neutrophils from blood and 
tumor became apoptotic when ROS were diminished.  
Moreover, the death receptor Fas has been shown to be involved in spontaneous extrinsic cell 
death signaling in neutrophils (Liles et al., 1996). Even though Fas-ligand induced apoptosis 
is believed to be of no importance in steady state (Fecho et al., 1998), it has been 
demonstrated to be important under inflammatory conditions (Jonsson et al., 2005). Indeed, 
Fas has been shown to play a role in type I IFN-induced apoptosis in several types of 
neoplasias such as melanoma, multiple myeloma and chronic myeloid leukemia cells 
(Chawla-Sarkar et al., 2001; Selleri et al., 1997). Interestingly, the present work shows a 
significant reduction of Fas expressing neutrophils in tumors and lungs of Ifnb1
-/-
 mice. This 
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is in line with the decreased apoptosis rate of neutrophils derived from tumor-bearing Ifnb1
-/-
 
mice. Thus, IFN-β dependent up-regulation of Fas in neutrophils might serve as a potential 
additional factor responsible for shortening the life span of pro-angiogenic neutrophils in 
tumors of normal animals.  
Apoptosis is tightly regulated. In accordance, neutrophilic granulocytes constitutively express 
the pro-apoptotic Bcl-2 proteins Bax, Bak, Bid and Bik (Gabelloni et al., 2013). Especially 
Bax appears to play a major role in the regulation of neutrophilic life span, as Bax
-/-
 mice 
show a reduced frequency of spontaneous apoptosis of such cells, compared to littermate 
controls (Gardai et al., 2004). In line with this, extended life span of neutrophils under 
inflammatory conditions is associated with reduced Bax expression (Dibbert et al., 1999). 
Under steady state conditions however, the activity of Bax is antagonized by anti-apoptotic 
Bcl-2 proteins such as BCL-xL (García-Sáez, 2012). The present study clearly demonstrates 
that the expression of anti-apoptotic BCL-xL was low under IFN sufficient conditions, while 
the pro-apoptotic factor Bax was up-regulated. In contrast, in the absence of endogenous 
IFN-BCL-xL expression dominated over Bax, which is consistent with an extended life 
span of tumor infiltrating neutrophils in Ifnb1
-/-
 mice. Thus, endogenous IFN- drives the 
expression of Bax and BCL-xL in tumor infiltrating neutrophils towards a pro-apoptotic 
ratio. Consequently, a shorter life span of such cells is the result. Of note was the increased 
expression of both types of genes in tumor tissue, compared to blood. Apparently, after 
transmigration such genes are up-regulated and IFN- is taking part in the fine tuning of this 
process.  
As a direct consequence of mitochondrial membrane permeabilization and cytochrome c 
release into the cytoplasm, formation of the apotosome, including Apaf-1 oligomerization, is 
induced and passes in the activation of initiator caspase 9 (Li et al., 1997). Regarding 
neutrophil apoptosis, the intrinsic apoptosis pathway exhibits a low threshold requirement for 
cytochrome c, which is compensated by a high cytosolic expression of Apaf-1 (Murphy et al., 
2003). In line with this, no differences in cytochrome c release comparing neutrophils of 
tumor bearing WT or Ifnb1
-/-
 mice were detected in the present study. However, in the 
presence of IFN-Apaf-1 gene expression was significantly upregulated. As consequence, 
significantly lower caspase 9 activity was observed in TANs in the absence of this cytokine. 
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Not only the expression of genes of the Bcl-2 family or Apaf-1 is regulated by IFN- but 
also expression of the effector caspase 3. Again a dramatic increase in expression level was 
observed in tumors compared to blood and the process was again strongly influenced by IFN-
Extrapolating these data, one could speculate that the expression of a majority of members 
of the intracellular pathway leading to apoptosis are influenced by IFN- 
The final executors of apoptosis, like caspase 3 (Chang and Yang, 2000), are expressed as 
pro-enzymes that need proteolytic cleavage to be activated. Besides the remarkable down-
regulation of caspase 3 expression at the transcriptional level, the level of active caspase 3 
was reduced in neutrophils derived from tumors of Ifnb1
-/-
 mice. It is not clear whether IFN-
 directly influences the proteolytic activation of this enzyme. More likely, the higher 
expression of the pro-enzyme at the transcriptional level in WT animals, results in generation 
of increased amounts of active caspase 3.  
G-CSF has been identified as one of the major survival factors of neutrophilic granulocytes 
and is also involved in the regulation of neo-angiogenesis (Im et al., 2012). Moreover, G-CSF 
has been reported to reduce Bax expression (Dibbert et al., 1999), block its redistribution and 
restore its phosphorylation status thus leading to its inactivation. Via this mechanisms, G-
CSF is capable to repress caspase activation (Maianski et al., 2004). In line with the 
inhibition of apoptosis and the prolonged neutrophil survival in the absence of endogenous 
IFN-β, a strong increase of G-CSF expression was observed in neutrophils from different 
anatomical compartments. Consistent with this, significantly elevated serum levels of G-CSF 
were detected in tumor bearing Ifnb1
-/-
 mice. This might additionally explain the increased 
longevity of tumor infiltrating neutrophils. Moreover, an enhanced mobilization of immature 
neutrophils into circulation accompanied by a significantly faster turn over of these cells was 
detected in tumor bearing Ifnb1
-/-
 mice in comparison to wild type controls. This might also 
be due to the increased G-CSF level in these animals. As such, the regulation of G-CSF 
expression by different molecular mechanisms is responsible for the control of neutrophil 
homeostasis (Mayadas et al., 2014). One possible way how endogenous IFN- could be 
involved in this process would be via the regulation of IL-23 or IL-17 production. Especially 
the latter one is known to induce G-CSF and GM-CSF production by stromal cells and its 
expression can be induced by IL-23 (Croxford et al., 2012; Stark et al., 2005). Interestingly, 
IFN- has been demonstrated to inhibit the production of IL-17 by CD4+ T cells (Chen et al., 
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2009). In addition, the prolonged life span of neutrophils in the absence of endogenous IFN- 
could be responsible for an increased production of IL-23 by tissue macrophages due to a 
reduced frequency of neutrophil phagocytosis that normally curbs the production of this 
cytokine and therefore regulates G-CSF secretion (Smith et al., 2007; Stark et al., 2005).  
In conclusion, IFN-is involved in the regulation of the life span, mobilization and turn over 
of pro-angiogenic neutrophils via a plethora of different pathways and mechanisms that 
involve synergistic regulation of genes directly participating in apoptosis, but also indirect 
pathways like cytokine production. 
Importantly, most of the pro-apoptotic neutrophil features influenced by type I IFNs are also 
associated with N1 polarization of TAN. As such, a pro-apoptotic gene expression pattern 
including upregulation of the death receptor Fas (Fridlender et al., 2009) as well as an 
enhanced production of cytotoxic ROS (Zivkovic et al., 2007) are important characteristics of 
anti-tumor neutrophils. Further evidence for N1 neutrophil polarization by type I IFN is given 
by its capacity to facilitate the expression of co-stimulatory molecules like ICAM1, that was 
shown to be upregulated in N1 anti-tumor neutrophils upon tissue migration and activation 
(Piccard et al., 2012). ICAM1 is especially important for T cell activation under conditions 
that provide low co-stimulation via CD80 and CD86 (Lebedeva et al., 2005). It can induce 
the activation of cytotoxic CD8
+
 T cells (Chen et al., 1999) as well as repress the secretion of 
immunosuppressive IL-10 by activated CD4
+
 T cells (Labuda et al., 1998). Thus, regulation 
of ICAM1 expression by endogenous IFN- could be involved in tumor immunosurveillance. 
Another characteristic of N1 neutrophils is the secretion of TNF- (Fridlender and Albelda, 
2012) that was remarkably reduced in the absence of endogenous IFN- suggesting N2 
polarization of neutrophils. Indeed, anti-tumor neutrophils have been demonstrated to 
activate DCs via the secretion of TNF- (van Gisbergen et al., 2005a). Importantly, TNF- 
has additionally been demonstrated to induce neutrophil apoptosis (Ferrante, 1992). 
Therefore elevated production of TNF- by N1 neutrophils is in line with the observed 
shorter life span of such cells and IFN- can apparently influence this process.  
Similarly, the most prominent anti-tumor neutrophil feature, i.e. their ability to directly kill 
tumor cells (Gerrard et al., 1981; Zivkovic et al., 2007; Fridlender et al., 2009), appears to be 
controlled by IFN-. Neutrophils isolated from blood or tumors of Ifnb1-/- mice displayed a 
significantly reduced tumor killing capacity in comparison to wild type controls, independent 
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of mouse strain and tumor model. This is even more eminent, as the addition of rmIFN- into 
the culture completely rescued the function, indicating the possibility to re-polarize 
neutrophils by therapeutic intervention. The molecular mechanism potentially involved at 
this point could be the decreased neutrophilic ROS production due to IFN- deficiency. As 
such, oxidative damage caused by singlet oxygen has been demonstrated to mediate tumor 
cell lysis (Lichtenstein et al., 1989; Zivkovic et al., 2005). In line with this, N1 neutrophil 
polarization in response to TGF- antagonists induced tumor toxicity via enhanced ROS 
production (Fridlender et al., 2009).  
Although, some studies attribute T cell suppressive properties to N2 TAN (Fridlender et al., 
2009; Kousis et al., 2007; Di Carlo et al., 2001), other authors use this capacity to define 
granulocytic MDSCs (Gabrilovich and Nagaraj, 2009; Gabrilovich et al., 2012a). However, 
the neutrophil population characterized during the present work, did neither display the 
ability to repress T cell proliferation nor did it produce arginase 1, notwithstanding the pro-
tumorigenic function of such cells (Jablonska et al., 2010, 2013). 
Besides the IFN- dependency of N1 neutrophil characteristics demonstrated in the present 
work, the pro-angiogenic expression of c-myc, MMP-9 and VEGF (Jablonska et al., 2010) as 
well as the secretion of auto-attracting CXC chemokines (Jablonska et al., 2013) seem to be 
regulated by endogenous type I IFNs. Importantly, also in these experiments additional 
rmIFN- was able to reconstitute wild type gene expression. To this end, therapeutic usage of 
IFN- was tested for its effect on neutrophil polarization in the present study. Indeed, type I 
IFN therapy augmented several N1 characteristics of neutrophils associated to the primary 
tumor and the pre-metastatic lung. Of note, this was independent of mouse strain or tumor 
model. It apparently influenced neutrophils accumulating in the pre-metastatic niche to a 
higher extend than those associated with the primary lesion. This is most probably due the 
comparably low amounts of IFN- and the intravenous route of application used during the 
present work that preferentially supply strongly vascularized organs like the lung with 
therapeutic relevant concentrations of the cytokine. Anyway, agents abrogating the formation 
of a permissive pre-metastatic niche could be of substantial benefit for the clinical 
management of high risk patients. Nevertheless, future research on the therapeutic use of type 
I IFNs should carefully consider its effect on neutrophils. 
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5.3. Clinical relevance and concluding remarks 
Even though, type I IFNs such as IFN- and IFN- have been successfully used to treat 
different subtypes of solid tumors and hematologic malignancies, the exact molecular 
mechanisms of their action are still not clear (Wang et al., 2011). Besides direct cytostatic 
and cytotoxic effects (Murata et al., 2006) several beneficial immunomodulatory effects on 
NK cells, monocytes, macrophages, DCs, T cells and B cells have been attributed to type I 
IFNs (Bekisz et al., 2013). However, data linking type I IFN therapy and modulation of TAN 
phenotype are not available so far. The experiments performed during the present study 
clearly demonstrated a therapeutic effect of rmIFN- on neutrophil polarization under tumor 
conditions. More precisely, a clear shift towards an N1 like TAN phenotype was detected 
under low dose IFN- therapy in all mouse models applied, identifying neutrophils as 
important target cells of this treatment.  
Neutrophils themselves were recently identified as effector cells during antibody-mediated 
tumor therapy (van Egmond, 2008), gene-therapy (Souto et al., 2011) and therapeutic 
application of pathogen derived biologics for cancer treatment (Galluzzi et al., 2012a; 
Kandasamy et al., 2011). Especially the latter ones, such as Coley toxin or bacillus Clamet-
Guérin (BCG), are known to potently activate TLR signaling and induce a type I IFN 
mediated immune response (Kuchtey et al., 2006). Noteworthy, the connection of neutrophil 
and type I IFN effects regarding these therapies has not been investigated up to now. 
Obviously, further research on type I IFN inducing compounds could possibly help to 
identify potent anti-tumor agents acting on this basis.  
In conclusion the present work elucidates additional mechanisms controlling neutrophil 
polarization and highlights the tremendous therapeutic potential of this process. Moreover, it 
generates further insight to the underlying pathways responsible for tumor-induced type I 
IFN expression. In the long run this knowledge might be used to directly target and activate 
endogenous type I IFN production during cancer immunotherapy, for example to prevent 
tumor metastasis in an adjuvant situation or boost the therapeutic effects of anti-tumor 
therapies such as irradiation (Burnette et al., 2011). Additionally, determination of genetic 
variants regarding type I IFN induction and response in tumor patients could be used in terms 
of personalized medicine, for example to predict the outcome of certain therapies. 
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All in all, further research efforts regarding this topic will definitely lead to applicable new 
treatment strategies of diverse malignancies.  
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7. Appendices 
7.1. Abbreviations 
APCs – antigen presenting cells 
APC- allophycocyanin 
BM – bone marrow 
CDA – cytosolic DNA receptor 
cDCs – conventionsal dendritic cells 
DCFDA - 2´, 7´-dichlorfluorescein diacetate 
DCs – dendritic cells 
EDTA – ethylendiaminetetraacetic acid 
ELISA – enzyme-linked immunosorbent assay 
ER – endoplasmatic reticulum 
FACS – fluorescence activated cell sorting 
FCS – fetal calf serum 
Fig. – figure 
FITC – fluorescein isothiocyanate 
FSC – forward scatter characteristics 
i.e. – this is 
IFN – interferon 
IL – interleukin 
IMDM – Iscove´s modified Dulbecco´s medium 
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i.v. – intra venous 
LPS – lipopolysaccharide 
MFI – mean fluorescence intensity 
MHC – major histocompatibility cmplex 
PAMPs – pathogen associated molecular patterns 
PBS – phosphate buffered saline 
PCR – polymerase chain reaction 
PE – phycoerythrin 
PI – propidium iodide 
PRR – pathogene recognition receptors 
RIG - retinoic acid inducible gene 
SSC – side scatter characteristics 
TLR – toll like receptor 
WT – wild type 
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